<SEC-DOCUMENT>0001104659-26-040497.txt : 20260407
<SEC-HEADER>0001104659-26-040497.hdr.sgml : 20260407
<ACCEPTANCE-DATETIME>20260407172526
ACCESSION NUMBER:		0001104659-26-040497
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20260401
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260407
DATE AS OF CHANGE:		20260407

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SUPERNUS PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001356576
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35518
		FILM NUMBER:		26845834

	BUSINESS ADDRESS:	
		STREET 1:		9715 KEY WEST AVENUE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-838-2500

	MAIL ADDRESS:	
		STREET 1:		9715 KEY WEST AVENUE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUPERNUS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20060317
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2611273d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:supn="http://supernus.com/20260401">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_supn_supernus.com_20260401 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20260401_20260401 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001356576 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-04-01" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-04-01" id="Fact000004" name="dei:EntityCentralIndexKey">0001356576</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="supn-20260401.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-04-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001356576</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-04-01</xbrli:startDate>
        <xbrli:endDate>2026-04-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 18pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;<b></b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 18pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>FORM&#160;<span id="xdx_903_edei--DocumentType_c20260401__20260401_zMqceXBTWDHh"><ix:nonNumeric contextRef="AsOf2026-04-01" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Pursuant to Section&#160;13
or 15(d)&#160;of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Date of Report (Date of
earliest event reported): <b><span id="xdx_906_edei--DocumentPeriodEndDate_c20260401__20260401_zHs9zJzNhuJ7"><ix:nonNumeric contextRef="AsOf2026-04-01" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">April 1, 2026</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_905_edei--EntityRegistrantName_c20260401__20260401_zJawgJqv3Iu7"><b><ix:nonNumeric contextRef="AsOf2026-04-01" id="Fact000011" name="dei:EntityRegistrantName">Supernus
Pharmaceuticals, Inc.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;(Exact name of registrant
as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 99.8%; text-align: left; border-collapse: collapse">
<tr>
    <td style="text-align: center; width: 33%"><b><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20260401__20260401_zxUPLUZCG1w4"><ix:nonNumeric contextRef="AsOf2026-04-01" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="padding-top: 2px; padding-right: 2px; padding-left: 2px; vertical-align: top; text-align: center; width: 35%"><span id="xdx_90A_edei--EntityFileNumber_c20260401__20260401_zPweGfTD7otb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2026-04-01" id="Fact000013" name="dei:EntityFileNumber">001-35518</ix:nonNumeric></b></span></td>
    <td style="padding-top: 2px; padding-right: 2px; padding-left: 2px; vertical-align: top; text-align: center; width: 33%"><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20260401__20260401_zoZ99xBl6F34" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2026-04-01" id="Fact000014" name="dei:EntityTaxIdentificationNumber">20-2590184</ix:nonNumeric></b></span></td></tr>
<tr>
    <td style="text-align: center">(State or other jurisdiction of<br/>
incorporation or organization)</td>
    <td style="padding: 2px; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    File Number)</span></td>
    <td style="padding: 2px; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer Identification No.)</span></td></tr>
</table>
<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 99.8%; text-align: left; border-collapse: collapse">
<tr>
    <td style="padding: 2px; vertical-align: top; text-align: center; width: 39%"><span id="xdx_90E_edei--EntityAddressAddressLine1_c20260401__20260401_zJNwIdHzA8A6"><b><ix:nonNumeric contextRef="AsOf2026-04-01" id="Fact000015" name="dei:EntityAddressAddressLine1">9715
    Key West Ave</ix:nonNumeric></b></span></td>
    <td style="padding: 2px; vertical-align: bottom; text-align: center; width: 13%"><span id="xdx_90F_edei--EntityAddressCityOrTown_c20260401__20260401_znkTOOxcnwJ7"><b><ix:nonNumeric contextRef="AsOf2026-04-01" id="Fact000016" name="dei:EntityAddressCityOrTown">Rockville</ix:nonNumeric></b></span></td>
    <td style="text-align: center; width: 13%"><span id="xdx_905_edei--EntityAddressStateOrProvince_c20260401__20260401_zorMvUq99Dx6"><b><ix:nonNumeric contextRef="AsOf2026-04-01" id="Fact000017" name="dei:EntityAddressStateOrProvince">MD</ix:nonNumeric></b></span></td>
    <td style="padding: 2px; vertical-align: top; text-align: center; width: 35%"><span id="xdx_906_edei--EntityAddressPostalZipCode_c20260401__20260401_zlgnnJ2Waa3i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2026-04-01" id="Fact000018" name="dei:EntityAddressPostalZipCode">20850</ix:nonNumeric></b></span></td></tr>
<tr>
    <td style="padding: 2px; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
                                            of Principal Executive Offices)</span></td>
    <td style="padding: 2px; vertical-align: bottom; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="padding: 2px; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Registrant&#8217;s telephone
number, including area code: <b>(<span id="xdx_90B_edei--CityAreaCode_c20260401__20260401_zfwKmKjNfgtd"><ix:nonNumeric contextRef="AsOf2026-04-01" id="Fact000019" name="dei:CityAreaCode">301</ix:nonNumeric></span></b><b>) <span id="xdx_90A_edei--LocalPhoneNumber_c20260401__20260401_zZheDOdAgtok"><ix:nonNumeric contextRef="AsOf2026-04-01" id="Fact000020" name="dei:LocalPhoneNumber">838-2500</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Former name or former address,
if changed since last report.)</p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant to Section 12(b)
of the Exchange Act</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Title of
    each class</span></span></td>
    <td style="text-align: center; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Trading Symbol</span></span></td>
    <td style="text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Name of each
    exchange on which registered</span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span id="xdx_900_edei--Security12bTitle_c20260401__20260401_zJcqNOQaFSw9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-04-01" id="Fact000021" name="dei:Security12bTitle">Common
    Stock, $0.001 par value per share</ix:nonNumeric></span></td>
    <td style="text-align: center"><span id="xdx_907_edei--TradingSymbol_c20260401__20260401_zzQ5JBfnlt1a" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-04-01" id="Fact000022" name="dei:TradingSymbol">SUPN</ix:nonNumeric></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_90C_edei--SecurityExchangeName_c20260401__20260401_ztapifPEm1Ja"><ix:nonNumeric contextRef="AsOf2026-04-01" format="ixt-sec:exchnameen" id="Fact000023" name="dei:SecurityExchangeName">Nasdaq
    Stock Market</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LLC</span></td></tr>
  </table>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Check the appropriate box below if the Form&#160;8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="text-decoration: underline">see</span>
General Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_903_edei--WrittenCommunications_c20260401__20260401_zz9cKzmB1rUl" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-04-01" format="ixt:booleanfalse" id="Fact000024" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">Written communications pursuant to Rule&#160;425 under the Securities
Act (17 CFR 230.425)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_905_edei--SolicitingMaterial_c20260401__20260401_zkSsVPPMkrYk" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-04-01" format="ixt:booleanfalse" id="Fact000025" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act
(17 CFR 240.14a-12)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20260401__20260401_zplJyla7cimj" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-04-01" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under
the Exchange Act (17 CFR 240.14d-2(b))</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20260401__20260401_ziPxOxlRJRX1" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-04-01" format="ixt:booleanfalse" id="Fact000027" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under
the Exchange Act (17 CFR 240.13e-4(c))</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: justify; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Indicate by
check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20260401__20260401_zwFwow7wTDB5" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-04-01" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: justify; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="font-family: Wingdings">&#168;</span></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1.01&#160;Entry Into a Material Definitive
Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Entry into Asset Purchase Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April&#160;1, 2026, Supernus Pharmaceuticals,&#160;Inc.
(the &#8220;Company&#8221;) entered into an Asset Purchase Agreement (the &#8220;Agreement&#8221;), together with related ancillary transaction
documents, with Navitor Pharmaceuticals,&#160;Inc., a Delaware corporation (&#8220;Navitor&#8221;), Navitor Pharmaceuticals, LLC, a Delaware
limited liability company (&#8220;Navitor Parent,&#8221; and, together with Navitor, the &#8220;Sellers&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement is entered into as contemplated
by that certain Development and Option Agreement, dated April&#160;21, 2020 between the Company and Navitor, and that certain Binding
Memorandum of Understanding, dated May&#160;5, 2025, between the Company and Navitor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Agreement, the Company agreed to acquire
from the Sellers all of their right, title, and interest in certain assets, including intellectual property rights of any kind, inventory
and manufacturing materials, regulatory and clinical materials, permits, data and records, certain contract rights, and related goodwill,
in each case related to the compound known as NV-5138 or SPN-820 (the &#8220;Compound&#8221;), and all of Sellers&#8217; rights under
warranties, indemnities and all similar rights against Third Parties to the extent related to any of the foregoing (collectively, the
&#8220;Purchased Assets&#8221;). Unless otherwise defined herein, the capitalized terms used herein have the same meaning ascribed to
them in the Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Price consists of the Company&#8217;s
obligation to (i)&#160;effect and complete one (1)&#160;Phase 2b Study; and (ii)&#160;make several milestone payments of up to $350 million
contingent upon the achievement of specified development, regulatory and commercial milestones.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has agreed to use commercially reasonable
efforts to achieve the specified milestones. However, following completion of the Phase 2 Study, if the Company determines in its sole
reasonable discretion that such study was not successful, the Company will have no further obligation to pursue milestone achievement
or commercialization of the Compound.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span>&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement contains customary representations
and warranties, and covenant. It also contains customary indemnification provisions pursuant to which each party has agreed to indemnify
the other for losses arising from, among other things, breaches of representations, warranties and covenants. The Company may offset any
indemnification losses to which it is entitled against any Milestone Payments not yet paid to the Sellers, and may also recover against
Milestone Payments previously made. The Agreement also contains a five-year post-closing non-competition and non-solicitation covenant
applicable to the Restricted Parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing summary does not purport to be complete
and is qualified in its entirety by reference to the Agreement, which is filed as an exhibit to this Current Report on Form&#160;8-K and
incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 2.01 Completion of Acquisition or Disposition of Asset.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information set forth in Item 1.01 of this
Current Report on Form&#160;8-K is incorporated by reference into this Item 2.01.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#160;Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><a href="tm2611273d1_ex2-1.htm" style="-sec-extract: exhibit">Exhibit&#160;2.1*&#8224; - Asset Purchase Agreement dated April&#160;1, 2026, by and among Supernus Pharmaceuticals,&#160;Inc., Navitor Pharmaceuticals,&#160;Inc. and Navitor Pharmaceuticals, LLC.</a></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Exhibit&#160;104 - The cover page&#160;from
this Current Report on Form&#160;8-K, formatted in Inline XBRL.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">* Exhibits and schedules have been omitted
pursuant to Regulation S-K Item 601(a)(5)&#160;and will be furnished on a supplemental basis to the Securities and Exchange Commission
upon request.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#8224; Certain portions of this exhibit
(indicated by asterisks) have been omitted because they are not material and would be competitively harmful if publicly disclosed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span>&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUPERNUS PHARMACEUTICALS,&#160;INC.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATED: April&#160;7, 2026</span></td>
    <td style="vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Timothy C. Dec</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy C. Dec</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Vice President and Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span>&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OUw3i/AxqYgsQiJ6XXSKJd2R2c3qk/rLNiUaBobh3nOvECOxppWukeG8KHI4YtPWyiEUeEFGU6J3ZJttCv4WeNXWsTKuf39gRp5Bz0xDKUsv9NZOW6xSiGbjOBnLBKJ5mkzgsBPBV8/IXHSFxmlVgzIVHJha1ugUv4aEo3qSoebVV52QrSaTQhxGg/wGGcUS9tSpB/HNQp5nIhj1E4g10731ruXTofmSsKyx8XV2oP8bfAALLkqU -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>tm2611273d1_ex2-1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 2.1&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CERTAIN CONFIDENTIAL INFORMATION IDENTIFIED IN THIS DOCUMENT MARKED
BY ***, HAS BEEN EXCLUDED FROM THE EXHIBIT&nbsp;BECAUSE IT IS BOTH (I)&nbsp;NOT MATERIAL AND (II)&nbsp;WOULD BE COMPETITIVELY HARMFUL
IF PUBLICLY DISCLOSED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSET PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Asset Purchase Agreement
(this &ldquo;<B>Agreement</B>&rdquo;), dated effective as of April&nbsp;1, 2026, is entered into by and between Navitor Pharmaceuticals,&nbsp;Inc.,
a Delaware corporation (&ldquo;<B>Navitor</B>&rdquo;), Navitor Pharmaceuticals, LLC, a Delaware limited liability company (&ldquo;<B>Navitor
Parent</B>,&rdquo; and, together with Navitor, the &ldquo;<B>Sellers</B>&rdquo;), and Supernus Pharmaceuticals,&nbsp;Inc., a Delaware
corporation (&ldquo;<B>Buyer</B>&rdquo;). Buyer, Navitor and Navitor Parent may each be referred to as a &ldquo;<B>Party</B>,&rdquo; or
collectively referred to as the &ldquo;<B>Parties</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, Buyer is a
public, CNS specialty pharmaceutical company with assets in neurology and a late-stage pipeline in psychiatry;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>WHEREAS</B>, Sellers Control the Product and the Purchased
IP;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, on April&nbsp;21,
2020, Buyer and Navitor entered into that certain Development and Option Agreement (the &ldquo;<B>Development Agreement</B>&rdquo;), pursuant
to which (i)&nbsp;Buyer and Navitor jointly conducted a Phase 2b Study (as defined herein) pursuant to a mutually agreed upon development
plan, with Buyer providing research and development support activities, and (ii)&nbsp;Navitor granted to Buyer an exclusive option to
either license or purchase the Product Intellectual Property (the &ldquo;<B>Option</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, after the
results of the Phase 2b Study, on May&nbsp;5, 2025, Buyer and Navitor entered into that certain Binding Memorandum of Understanding (the
 &ldquo;<B>MOU</B>&rdquo;), pursuant to which MOU, (i)&nbsp;Buyer exercised the Option, and (ii)&nbsp;Buyer and Navitor agreed to amend
the terms of the Option as contemplated by the Development Agreement, including the waiver of the Initial Acquisition Fee (as defined
in the Development Agreement); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, after review,
Buyer has determined to purchase certain assets of the Sellers relating to the Compound rather than the equity of Navitor; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, this Agreement
is the purchase agreement contemplated in the Development Agreement and MOU relating to the sale by Sellers and the purchase by Buyer
of certain assets of Sellers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;I<BR>
DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;1.01 Defined
Terms. </B>The following terms have the meanings specified or referred to in this <U>ARTICLE&nbsp;I</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Action</B>&rdquo;
means any claim, action, charge, cause of action, demand, lawsuit, arbitration, audit, notice of violation, proceeding, litigation, citation,
summons, petition or subpoena of any nature, civil, criminal, administrative, regulatory or otherwise, whether at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is
under common control with, such Person. The term &ldquo;control&rdquo; (including the terms &ldquo;controlled by&rdquo; and &ldquo;under
common control with&rdquo;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management
and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Agreement</B>&rdquo; has the
meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Allocation Schedule</B>&rdquo; has the meaning set forth in <U>Section&nbsp;2.05</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Annual Net Sales</B>&rdquo;
means, with respect to any Calendar Year, the aggregate amount of Net Sales for such Calendar Year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Assignment and Assumption
Agreement</B>&rdquo; has the meaning set forth in <U>Section&nbsp; 3.02(a)(iii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Assignment of Patents</B>&rdquo; has the meaning
set forth in <U>Section&nbsp;3.02(a)(iv)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Assumed Liabilities</B>&rdquo; has the meaning
set forth in <U>Section&nbsp;2.03</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Bill of Sale</B>&rdquo; has the meaning set forth
in <U>Section&nbsp;3.02(a)(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business Day</B>&rdquo;
means any day except Saturday, Sunday or any other day on which commercial banks located in New York, New York are authorized or required
by Law to be closed for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business Representative</B>&rdquo;
means, with respect to any Person, any and all directors, officers, employees, consultants, financial advisors, counsel, accountants and
other business representatives of such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Buyer</B>&rdquo; has the meaning set forth in the
preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Calendar Year</B>&rdquo; means each successive
period of twelve (12) months commencing on January&nbsp;1 and ending on December&nbsp;31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Closing</B>&rdquo; has the meaning set forth in
<U>Section&nbsp;3.01</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Closing Date</B>&rdquo; has the meaning set forth
in <U>Section&nbsp;3.01</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Code</B>&rdquo; means the Internal Revenue Code
of 1986, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Commercialize</B>&rdquo;
means any and all activities directed to the promotion, marketing, distribution or sale (and offer for sale or import or export for sale
or use) for a Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Commercializing</B>&rdquo; and &ldquo;<B>Commercialization</B>&rdquo;
have corresponding meanings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Commercially Reasonable
Efforts</B>&rdquo; means those efforts and resources commensurate with those efforts commonly used in the pharmaceutical industry by a
company of comparable size and resources as Buyer in connection with the Development and Commercialization of a pharmaceutical product
of similar commercial potential as a Product and at a similar stage in such product&rsquo;s lifecycle, taking into account the proprietary
position of the Product (including with respect to patent or regulatory exclusivity, intellectual property scope, subject matter and coverage),
safety and efficacy, Product profile, the competitiveness of other products in development and/or in the marketplace, the regulatory status
and approval process, anticipated or approved labeling, market potential, the profitability of the Product (including pricing and reimbursement
status), and other relevant technical, legal, scientific or medical factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Compound</B>&rdquo;
means a compound having the structure set forth below (also known as NV-5138 or SPN-820), including any analogs, isomers, esters, salts,
hydrates, solvates, and solid forms, including crystalline forms, thereof, including whether or not as the sole active ingredient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">***</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Computer Systems</B>&rdquo;
means any of, or combination of, the owned and Third Party computer software, computer firmware, computer hardware (whether general or
special purpose), telecommunications capabilities (including voice, data or video networks), networks, peripherals, platforms, computer
systems, accounts with and subscriptions to Third Party databases, SaaS systems and the like, and other similar or related items of any
automated, computerized or software system and any other network, system, resource or related service used by Sellers in connection with
the ownership, use, or Exploitation of the Compound or any Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Contracts</B>&rdquo;
means all legally binding written contracts, leases, mortgages, licenses, consent to use agreements, instruments, notes, commitments,
undertakings, indentures and other agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Control</B>&rdquo;
or &ldquo;<B>Controlled</B>&rdquo; means with respect to any *** or *** or other intellectual property right, the legal
authority or right (whether by ownership, license or otherwise) of a Person to grant a license or a sublicense of or under such
***, *** or other intellectual property right to another Person, without breaching the terms of any agreement with, or
misappropriating the proprietary or trade secret information of, or requiring the consent of, a Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Cover</B>&rdquo;,
 &ldquo;<B>Covering</B>&rdquo; or &ldquo;<B>Covered</B>&rdquo; means with respect to a product, technology, process or method, that
in the *** of *** of or a *** granted under (a)&nbsp;a claim of an issued patent that has not expired or been
abandoned, or been revoked, held invalid or unenforceable by a patent office, court or other governmental agency of competent
jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time period)
and that is not admitted to be invalid or unenforceable through reissue, disclaimer or otherwise (i.e., only to the extent the
subject matter is disclaimed or is sought to be deleted or amended through reissue); or (b)&nbsp;a claim of a pending patent
application that was filed in good faith and has not been (i)&nbsp;abandoned, finally rejected or expired without the possibility of
appeal or refiling, or (ii)&nbsp;pending for more than seven (7)&nbsp;years since such claim was first presented in unamended form
(each, a &ldquo;<B>Valid Claim</B>&rdquo;), the Exploitation of such product, technology, process or method would infringe such
Valid Claim (or, in the case of a Valid Claim that has not yet issued, would infringe such a claim then existing if it were to be
issued as a Valid Claim).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Development</B>&rdquo;
means discovery and research activities and any and all development activities, including non-clinical, preclinical and clinical trials,
post approval studies, supporting manufacturing, production process development and formulation and related regulatory activities, directed
to obtaining and maintaining Regulatory Approval for a product. &ldquo;<B>Develop</B>&rdquo; and &ldquo;<B>Developing</B>&rdquo; have
corresponding meanings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Development Agreement</B>&rdquo; has the meaning
set forth in the Recitals. &ldquo;<B>Direct Claim</B>&rdquo; has the meaning set forth in <U>Section&nbsp;7.05(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Disclosure Schedules</B>&rdquo;
means the Disclosure Schedules delivered by Sellers and Buyer concurrently with the execution and delivery of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Dollars or $</B>&rdquo; means the lawful currency
of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Encumbrance</B>&rdquo;
means any charge, claim, community property interest, pledge, condition, equitable interest, mortgage, security interest, deed of trust,
lien (statutory or other), option, security interest, mortgage, easement, encroachment, right of way, right of first refusal, or restriction
of any kind, including any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Excluded Assets</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.02</U>. &ldquo;<B>Excluded Liabilities</B>&rdquo; has the meaning set forth in <U>Section&nbsp;2.03</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Exploit</B>&rdquo;
means to make, have made, import, have imported, use, sell or offer for sale, including to ***, register,
hold or keep (whether for disposal or otherwise), have used, export, have exported, transport, distribute, promote, market, have sold,
have offered for sale, or otherwise exploit. &ldquo;<B>Exploitation</B>&rdquo; means the act of ***.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>FDA</B>&rdquo; means
the United States Food and Drug Administration and all divisions under its direct control or any successor organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>FDCA</B>&rdquo;
means the Federal Food, Drug, and Cosmetic Act, as amended, and its respective implementing orders and regulations, or any similar Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Fraud</B>&rdquo;
means common law fraud under the Laws of the State of Delaware that is intentional or made with actual knowledge or with a reckless
disregard of the truth with respect to the making of the representations and warranties contained in this Agreement or in any
Transaction Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>GAAP</B>&rdquo; means United States generally
accepted accounting principles in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Governmental Authority</B>&rdquo;
means any federal, state, local or foreign government or political subdivision thereof, or any agency or instrumentality of such government
or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority
(to the extent that the rules, regulations or orders of such organization or authority have the force of Law), or any arbitrator, court
or tribunal of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Governmental Order</B>&rdquo;
means any order, writ, judgment, injunction, decree, stipulation, determination, or award entered by or with any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Healthcare Laws</B>&rdquo;
means, to the extent applicable, all Laws relating to research (including preclinical, nonclinical, and clinical research or studies),
development, testing, production, manufacture, transfer, storing, distribution, approval, labeling, marketing, promotion, pricing, third-party
reimbursement or sale of drugs, including (i)&nbsp;the FDCA; (ii)&nbsp;any federal health care program (as such term is defined in 42
U.S.C. &sect; 1320a-7b(f)), including the federal Anti-Kickback Statute (42 U.S.C. &sect; 1320a-7b(b)), the civil False Claims Act (31
U.S.C. &sect; 3729 et seq.), the administrative False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), Sections 1320a-7 and 1320a-7a of Title
42 of the United States Code, Medicare (Title XVIII of the Social Security Act) and Medicaid (Title XIX of the Social Security Act); (iii)&nbsp;all
comparable state, local or foreign Laws; and (iv)&nbsp;the rules&nbsp;and regulations promulgated pursuant to (i)-(iii)&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>HIPAA</B>&rdquo;
means, collectively, the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology
for Economic and Clinical Health Act of 2009, and the HIPAA Final Omnibus Rule&nbsp;issued on January&nbsp;17, 2013, and all associated
rules&nbsp;and regulations, and all similar Canadian laws and any other applicable non-U.S. Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Indemnified Party</B>&rdquo; has the meaning
set forth in <U>Section&nbsp;7.04</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Indemnifying Party</B>&rdquo; has the meaning set forth in <U>Section&nbsp;7.04</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Independent Accountant</B>&rdquo; has the meaning set forth in <U>Section&nbsp;2.05</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Intellectual Property</B>&rdquo;
means any and all of the following arising pursuant to the Laws of any jurisdiction throughout the world including: (a)&nbsp;registered
and unregistered trademarks, service marks, trade names, trade dress, and similar indicia of source of origin, all registrations and applications
for registration thereof, and the goodwill connected with the use of and symbolized by the foregoing; (b)&nbsp;registered and unregistered
copyrights and all registrations and applications for registration thereof; (c)&nbsp;trade secrets; (d)&nbsp;Patents; (e)&nbsp;internet
domain name registrations; and (f)&nbsp;other intellectual property and related proprietary rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Intellectual
Property Registrations</B>&rdquo; means any Intellectual Property that is subject to any issuance, registration, application or
other filing by, to or with any Governmental Authority or authorized private registrar in any jurisdiction, including registered
trademarks, domain names, and copyrights, issued and reissued Patents and pending applications for any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Inventory</B>&rdquo; has the meaning set forth
in <U>Section&nbsp;2.01(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Know-How</B>&rdquo;
means all information, materials and know-how including technology, experience, discoveries, improvements, enhancements, modifications,
processes, formulae, data (including all preclinical, clinical, toxicological and pharmacological data), proprietary information and applicable
trade secrets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Knowledge of
the Sellers</B>&rdquo; or any other similar knowledge qualification, means the actual knowledge, after reasonable due inquiry, of
*** and ***.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Law</B>&rdquo; means
any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, decree, other requirement or rule&nbsp;of
law of any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Liabilities</B>&rdquo;
means liabilities, obligations or commitments of any nature whatsoever, asserted or unasserted, known or unknown, absolute, contingent
or threatened, accrued or unaccrued, matured or unmatured, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Losses</B>&rdquo;
or &ldquo;<B>Losses</B>&rdquo; means losses, damages, Liabilities, deficiencies, Actions, judgments, interest, awards, penalties, fines,
costs or expenses of whatever kind, including reasonable attorneys&rsquo; fees and court costs, the cost of enforcing any right to indemnification
hereunder and the cost of pursuing any insurance providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Manufacture</B>,&rdquo;
 &ldquo;<B>Manufacturing</B>&rdquo; or any derivative thereof means, with respect to a particular active pharmaceutical ingredient, excipient,
other ingredient, or product as a whole, all steps in propagation or manufacture and preparation of the foregoing, including the manufacturing,
processing, filling, formulating, testing (including in-process testing), packaging, labeling, holding and storing, quality control testing
and release of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Material Adverse
Effect</B>&rdquo; means any event, occurrence, fact, condition or change that is, or could reasonably be expected to become, individually
or in the aggregate, materially adverse to (a)&nbsp;the value of the Purchased Assets, or (b)&nbsp;the ability of Sellers to consummate
the transactions contemplated hereby; <I>provided</I>, <I>however</I>, that Material Adverse Effect shall not include any event, occurrence,
fact, condition or change, directly or indirectly, arising out of or attributable to: (i)&nbsp;general economic or political conditions;
(ii)&nbsp;conditions generally affecting the industries in which the Sellers operate; (iii)&nbsp;any changes in financial, banking or
securities markets in general, including any disruption thereof and any decline in the price of any security or any market index or any
change in prevailing interest rates; (iv)&nbsp;acts of war (whether or not declared), armed hostilities or terrorism, or the escalation
or worsening thereof; (v)&nbsp;any action required or permitted by this Agreement or any action taken (or omitted to be taken) with the
written consent of or at the written request of Buyer; (vi)&nbsp;the public announcement, pendency or completion of the transactions contemplated
by this Agreement; (vii)&nbsp;any changes in applicable Laws; or (viii)&nbsp;any epidemics, pandemics, disease outbreaks, or other public
health emergencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Milestone</B>&rdquo; has the meaning set forth
in <U>Section&nbsp;2.04</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Milestone Payment</B>&rdquo; has the meaning set forth in <U>Section&nbsp;2.04</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>MOU</B>&rdquo; has the meaning set forth in the
Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>NDA</B>&rdquo; means a new drug application for
a drug filed in accordance with 21 C.F.R. Part 314.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>NDA Approval</B>&rdquo; means Regulatory Approval
from by the FDA of an NDA for a Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Net Sales</B>&rdquo; means the gross
amount invoiced for Sales of Products less all applicable deductions from such gross sales, all as determined in accordance with standard
practices for other pharmaceutical products and consistent with the customary practices in the pharmaceutical industry, consistently applied,
and which, as applicable, are actually incurred, allowed, accrued, or specifically allocated, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>cash
discounts, quantity discounts, prompt payment discounts, promotional discounts, stocking, or other promotional allowances;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Sales
and excise Taxes, customs levies and any other duties or Taxes and shipping, freight, and transportation costs (including insurance costs),
all to the extent added to the Sale price and paid and not refundable in accordance with applicable Law (but not including Taxes assessed
against the income derived from such Sale);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>returns,
recalls and returned goods refunds, credits and allowances;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>retroactive
corrections, including price adjustments (including those on customer inventories following price changes) and corrections for billing
errors or shipping errors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>chargebacks,
rebates, administrative fees, any other allowances (including shelf stock adjustments, slotting allowances and inventory price adjustments)
actually granted or allowed to any Person, including group purchasing organizations, managed health care organizations, and to governments,
including their agencies, or to trade customers, in each case that are not Affiliates of Buyer, and that are directly attributable to
the Sale of a Product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(f)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>rebates
and similar payments made with respect to sales paid for by Federal or state Medicaid, Medicare, or similar state program in the United
States (including Medicaid and Supplemental State program rebates, Medicare Part&nbsp;D &ldquo;Donut Hole&rdquo; Coverage Gap rebates);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>redistribution
center (RDC) fees, information service agreement (ISA) fees, and like fees that are customary in the industry that are passed from wholesalers,
retailers, distributors, and other customers back to Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the sake of clarity,
all such deductions represent reductions to the gross amount invoiced for Sales of Products by Buyer or its Affiliates to Third
Parties in accordance with U.S. GAAP or in the case of non-United States Sales, other applicable accounting standards (consistently
applied).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Offset Amount</B>&rdquo; has the meaning set forth
in <U>Section&nbsp;7.06</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Option</B>&rdquo; has the meaning set forth in
the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Party</B>&rdquo; and &ldquo;<B>Parties</B>&rdquo;
have the meanings set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Patents</B>&rdquo;
means (a)&nbsp;all patents and patent applications (provisional and non-provisional), including all analog statements contained therein,
in each case anywhere in the world, including Patent Cooperation Treaty (&ldquo;<B>PCT</B>&rdquo;) applications, (b)&nbsp;all divisionals,
continuations, continuations in-part thereof, or any other patent application claiming priority, or entitled to claim priority, directly
or indirectly to (i)&nbsp;any such patents or patent applications or (ii)&nbsp;any patent or patent application from which such patents
or patent applications claim, or is entitled to claim, direct or indirect priority, and (c)&nbsp;all patents issuing on any of the foregoing
anywhere in the world (including from PCT applications), together with all registrations, reissues, re-examinations, patents of addition,
utility models or designs, renewals, substitutes, supplemental protection certificates, or extensions of any of the foregoing and counterparts
thereof anywhere in the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permits</B>&rdquo;
means all permits, licenses, franchises, approvals, authorizations, registrations, approvals, and consents required to be obtained from
Governmental Authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo;
means an individual, corporation, partnership, joint venture, limited liability company, Governmental Authority, unincorporated organization,
trust, association or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Personal Information</B>&rdquo;
means all &ldquo;personal data,&rdquo; &ldquo;personal information,&rdquo; &ldquo;personally identifiable information,&rdquo; &ldquo;PII,&rdquo;
or any similar type of information that is subject to any Privacy Requirements, including without limitation personally identifiable health
information from any clinical trial participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B>Phase 2b Study</B>&rdquo; means a human
clinical study of a Product, the principal purpose of which is a determination of safety and efficacy in the target patient population,
as described in 21 C.F.R. 312.21(b)&nbsp;(as amended or any replacement thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Phase 3 Study</B>&rdquo;
means a human clinical study of a Product that incorporates FDA accepted endpoints for confirmation of statistical significance of efficacy
and safety with the aim to generate data and results that can be submitted to obtain Regulatory Approval as described in 21 C.F.R. 312.21(c)&nbsp;(as
amended or any replacement thereof), or a similar clinical study prescribed by the Regulatory Authority in a country other than the United
States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Privacy Requirements</B>&rdquo;
means all applicable Laws and contractual requirements in all relevant jurisdictions concerning the privacy, security, collection, use,
storage, retention, disclosure, transfer, disposal, or any other processing of any personal information by either Seller and each Seller&rsquo;s
privacy policies and the requirements of any Contract or codes of conduct to which such Seller is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Product</B>&rdquo; means any product containing
the Compound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Product Intellectual
Property</B>&rdquo; means all Product Patents, Product Know-How, and all other Intellectual Property that in each case are Controlled
by Sellers and related to the Compound or any Product or the Exploitation thereof in any way whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Product Intellectual
Property Registrations</B>&rdquo; has the meaning set forth in <U>Section&nbsp;4.06(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Product Know-How</B>&rdquo;
means any and all Know-How that is necessary or reasonably useful to Exploit the Compound or any of the Products and is Controlled by
either Seller as of the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Product Patents</B>&rdquo;
means any and all Patents that Cover the Compound or any of the Products or the Exploitation thereof and, in each case, are Controlled
by either Seller or any of their Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Purchase Price</B>&rdquo; has the meaning set
forth in <U>Section&nbsp;2.04</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Purchased Assets</B>&rdquo; has the meaning set
forth in <U>Section&nbsp;2.01</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Purchased IP</B>&rdquo; has the meaning set forth in <U>Section&nbsp;4.06(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Regulatory and Clinical
Materials</B>&rdquo; means: (i)&nbsp;regulatory applications, submissions and approvals (including all investigational new drug applications
(&ldquo;<B>INDs</B>&rdquo;), NDAs, applications, and foreign counterparts thereof) (and any supplements or amendments thereto) that relate
to Compound or any Product; (ii)&nbsp;any notifications, communications, correspondence, minutes of meetings or telephone conversations,
registrations, letters of authorization for master files, or other filings made to, received from or otherwise conducted with FDA and
other Governmental Authorities; (iii)&nbsp;records and other materials maintained to comply with applicable Healthcare Laws (e.g., regarding
good laboratory practice, good clinical practice and good manufacturing practice, as applicable); (iv)&nbsp;preclinical, nonclinical and
clinical research data, results, outcomes, laboratory books or databases, information regarding adverse events, side effects, toxicity
and safety, notes, reports and other information (excluding in all cases the medical records of any human research subjects) collected,
generated or derived directly from the conduct of any study of any Product, and (v)&nbsp;records that are necessary in order to obtain
and maintain Permits or approvals from Governmental Authorities under applicable Healthcare Laws for the research, development, testing,
production, manufacture, transfer, distribution, approval, labeling, marketing, pricing, third-party reimbursement or sale of drugs and
all amendments, supplements, supporting files, data, studies, and reports relating thereto (in hard and electronic form) and all technical
and other information contained therein, and all correspondence with the FDA and other Governmental Authorities relating to the foregoing,
that, in each case, are in the possession of or are Controlled by any Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Regulatory Approval</B>&rdquo;
means any and all approvals, licenses, registrations or authorizations of any Regulatory Authority, necessary to commercially manufacture,
distribute, sell or market a product in a country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Regulatory
Authority</B>&rdquo; means any national, supranational, regional, state or local regulatory agency, department, bureau, commission,
council or other Governmental Authority (including the FDA and the European Medicines Agency, and any successor or replacement
agency, and any other agencies in any country) regulating or otherwise exercising authority with respect to the Exploitation of
pharmaceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Related Party</B>&rdquo; has
the meaning set forth in <U>Section&nbsp;4.14</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Relevant Contracts</B>&rdquo; has the meaning set forth in <U>Section&nbsp;4.05</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Restricted Business</B>&rdquo;
means any business that develops, Exploits, Manufactures, sells or licenses any compound or product in the field of mental health disorders
that positively modulates mTORC1 activity as its principal mechanism of action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Sale</B>&rdquo;
shall mean any arms-length transaction to a Third Party purchaser with respect to a country, after Regulatory Approval in such country,
in exchange for cash or some equivalent to which value can be assigned. A Sale of a Product will be deemed to have been made on the date
on which Buyer, its Affiliates or its sublicensees receive value for such Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Sellers</B>&rdquo; has the meaning set forth in
the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Taxes</B>&rdquo;
means all federal, state, local, foreign and other income, gross receipts, sales, use, production, ad valorem, transfer, franchise, registration,
profits, license, lease, service, service use, withholding, payroll, employment, unemployment, estimated, excise, severance, environmental,
stamp, occupation, premium, property (real or personal), real property gains, windfall profits, customs, duties or other taxes, fees,
assessments or charges of any kind whatsoever, together with any interest, additions or penalties with respect thereto and any interest
in respect of such additions or penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Third Party</B>&rdquo;
shall mean any entity other than Sellers or Buyer and their respective Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Third-Party Claim</B>&rdquo; has the meaning set
forth in <U>Section&nbsp;7.05(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Transaction Documents</B>&rdquo; has the meaning
set forth in <U>Section&nbsp;3.02(a)(iv)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Whitehead Letter</B>&rdquo; has the meaning set forth in <U>Section&nbsp;6.08</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Whitehead License</B>&rdquo;
means that certain Exclusive Patent License Agreement, dated effective as of November&nbsp;30, 2015, by and between Whitehead Institute
for Biomedical Research, a Delaware corporation (&ldquo;<B>Whitehead</B>&rdquo;), and Navitor, as amended by that certain First Amendment,
effective as of March&nbsp;5, 2018, that certain Second Amendment, effective as of July&nbsp;1, 2022, and that certain Third Amendment,
effective as of April&nbsp;1, 2026, attached hereto as <U>Exhibit&nbsp;F</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURCHASE AND SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;2.01
Purchase and Sale of Assets. </B>Subject to the terms and conditions set forth herein, at the Closing, Sellers shall sell, assign,
transfer, convey and deliver to Buyer, and Buyer shall purchase from Sellers, free and clear of any Encumbrances, all of
Sellers&rsquo; right, title and interest in the assets set forth below (collectively, the &ldquo;<B>Purchased
Assets</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
Purchased IP, including, without limitation, the Purchased IP listed on Section&nbsp;4.06(a)&nbsp;of the Disclosure Schedules;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
starting materials, excipients, raw materials, drug substance, master cell banks, working cell banks, cell lines, process consumables,
vials, stoppers, syringes, media, feed, resins, reagents, packaging and labeling components, and all other supplies of any kind used in
connection with manufacturing, packaging and shipping any Product (the &ldquo;<B>Inventory</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
Regulatory and Clinical Materials;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
Transferred Permits;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
electronic files and records relating to the Compound;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
of Sellers&rsquo; rights under warranties, indemnities and all similar rights against Third Parties to the extent related to any of the
foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
rights to receive mail and other communications related to the Compound or any Product; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
goodwill relating to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;2.02 Excluded
Assets. </B>Other than the Purchased Assets subject to <U>Section&nbsp;2.01</U>, Buyer expressly understands and agrees that it is not
purchasing or acquiring, and Sellers are not selling or assigning, any other assets or properties of Sellers, and all such other assets
and properties shall be excluded from the Purchased Assets (the &ldquo;<B>Excluded Assets</B>&rdquo;). For the avoidance of doubt, Excluded
Assets include the Whitehead License, the PATENT RIGHTS, TANGIBLE PROPERTY, and KNOW-HOW (as such terms are defined in the Whitehead License)
and any other rights granted to Navitor under the Whitehead License except to the extent specifically provided in the Whitehead Letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;2.03
Assumed Liabilities; Excluded Liabilities. </B>Subject to the terms and conditions set forth herein, Buyer shall assume and agree to
pay, perform and discharge only those Liabilities of the Sellers arising under the Purchased Assets arising after the Closing Date
(collectively, the &ldquo;<B>Assumed Liabilities</B>&rdquo;), and no other Liabilities; <I>provided, however</I>, that the Assumed
Liabilities shall not include any Liabilities (A)&nbsp;arising from or relating to any Relevant Contract, (B)&nbsp;arising from or
relating to any event, circumstance or condition occurring or existing on or prior to or after the Closing Date that, with notice or
lapse of time or both, would constitute or result in a breach by Sellers of any Relevant Contract, (C)&nbsp;arising from any
violation of Laws, breach of warranty, tort or infringement or other condition, fact or circumstance existing or occurring on or
before the Closing Date, or (D)&nbsp;arising from or related to any Excluded Asset (the &ldquo;<B>Excluded Liabilities</B>&rdquo;).
Other than the Assumed Liabilities, Buyer shall not assume any liabilities or obligations of Liabilities of Sellers or any of their
Affiliates, and Sellers shall, and shall cause each of their Affiliates to, pay and satisfy in due course all Excluded Liabilities
which they are obligated to pay and satisfy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;2.04 Purchase
Price. </B>As consideration for the Purchased Assets, Buyer shall (i)&nbsp;effect and complete one (1)&nbsp;Phase 2b Study, the design
and endpoints to be determined in Buyer&rsquo;s sole discretion, which will be conducted at such time and in such manner in Buyer&rsquo;s
sole discretion, and (ii)&nbsp;make the following one-time milestone payments (each, a &ldquo;<B>Milestone Payment</B>&rdquo;) (the &ldquo;<B>Purchase
Price</B>&rdquo;) shall equal the total of the following to Sellers upon the achievement of the corresponding milestone events (each,
a &ldquo;<B>Milestone</B>&rdquo;) set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>***
upon Buyer&rsquo;s completion of two positive (2)&nbsp;Phase 3 Studies that meet or otherwise satisfy the endpoints demonstrating the
safety and clinical efficacy of a Product that the FDA agrees will be sufficient to support submission of an NDA, payable within ten (10)&nbsp;Business
Days from Buyer&rsquo;s public announcement of such achievement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>***
upon the FDA&rsquo;s acceptance of an NDA filing for a Product, payable within ten (10)&nbsp;Business Days from Buyer&rsquo;s announcement
of its receipt of the FDA&rsquo;s acceptance of such NDA filing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>***
upon the NDA Approval, payable within ten (10)&nbsp;Business Days from Buyer&rsquo;s announcement of receipt of Regulatory Approval for
a Product from the FDA;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>***
upon Regulatory Approval for a Product by any Regulatory Authority in <FONT STYLE="font-size: 10pt">*** </FONT>(whichever occurs first,
but only upon receipt of the first such Regulatory Approval), payable within ten (10)&nbsp;Business Days from Buyer&rsquo;s announcement
of receipt of Regulatory Approval for a Product in <FONT STYLE="font-size: 10pt">***</FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>a
*** of *** upon Buyer receiving *** in Annual Net Sales of Products, payable within ten (10)&nbsp;Business
Days after Buyer&rsquo;s release of its annual financial statements for the applicable Calendar Year in which the Milestone has been achieved;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>a
*** payment of *** upon Buyer receiving *** in Annual Net Sales of Products, payable within ten
(10)&nbsp;Business Days after Buyer&rsquo;s release of its annual financial statements for the applicable Calendar Year in which the
Milestone has been achieved; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>a
*** payment of *** upon Buyer receiving *** in Annual Net Sales of Products, payable within ten
(10)&nbsp;Business Days after Buyer&rsquo;s release of its annual financial statements for the applicable Calendar Year in which the
Milestone has been achieved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Buyer shall promptly
inform Sellers of the achievement of each Milestone by Buyer or any of its Affiliates. In the event that the development of a
Product permits Buyer to skip a Milestone for which a Milestone Payment would have otherwise been due, upon the achievement of the
next Milestone for such Product, such skipped Milestone shall be deemed to have been achieved, and in addition to the Milestone
Payment for such next Milestone Buyer shall pay to Sellers the amount due for the skipped Milestone which shall be deemed achieved.
The Sellers agree that any Milestone Payment may be reduced pursuant to the provisions of <U>Section&nbsp;7.06</U>. Buyer may, and
the Sellers hereby agree and consent to, provide notice of the achievement of each Milestone and of the payment of any corresponding
Milestone Payment to Whitehead. Buyer shall use Commercially Reasonable Efforts to achieve each Milestone set forth in <U>Section&nbsp;2.04(a)</U>&nbsp;through
(g); <I>provided</I>, <I>however</I>, that Buyer shall not be obligated to use Commercially Reasonable Efforts or any efforts to
achieve any Milestone, and all of Buyer&rsquo;s obligations under this Agreement with respect to the Commercialization of the
Compound or any Product shall cease, upon Buyer&rsquo;s completion of the Phase 2 Study and determination, in Buyer&rsquo;s sole
reasonable discretion, that the Phase 2 Study was not successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything to
the contrary in this Agreement, (i)&nbsp;the right of Sellers to receive the Milestone Payments may be assigned to any third party and
(ii)&nbsp;the Sellers will be able to enter into a monetization transaction with respect to any of the Milestone Payments, <I>provided
</I>in each case that (y)&nbsp;the rights of any assignee or monetization counterparty shall be subject to Buyer&rsquo;s rights of offset
under this Agreement, and (z)&nbsp;with the prior consent of Buyer, which consent will not be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From and after the
Closing Date, Buyer shall provide to the Sellers, within 90 days of the end of each calendar year, a reasonably detailed written
report of its activities and progress toward achievement of the Milestones during the immediately preceding twelve (12) month period
(and, for the first such report, since the Closing Date), including information concerning status of any proposed or current
clinical Development of the Product (including all proposed indications for which Development is being sought), results of relevant
clinical trials and Development, and any current or planned Regulatory Approvals being sought and the status of such prospective
Regulatory Approvals, including projected timelines (the &ldquo;<B>Milestone Reports</B>&rdquo;). At least once annually upon
written request from Sellers, Buyer agrees to meet with an appropriate representative of the Sellers on such date as and time to be
agreed upon by Buyer and the Sellers and during normal business hours for the purposes of discussing the Milestone Reports.
Notwithstanding the foregoing, Buyer&rsquo;s obligations to prepare and deliver a Milestone Report and to meet with Sellers as set
forth in this paragraph shall cease upon Buyer&rsquo;s notice to Sellers that, in Buyer&rsquo;s sole reasonable discretion, that the
Phase 2 Study was not successful; <I>provided</I>, <I>however</I>, that Buyer shall (i)&nbsp;provide a Milestone Report and readout
with respect to such Phase 2 Study and (ii)&nbsp;meet with *** (or if *** is not available, another representative of the Sellers
reasonably acceptable to Buyer) on such date as and time to be agreed upon by Buyer and the Sellers and during normal business hours
for the purposes of reviewing such final Milestone Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;2.05
Allocation of Purchase Price. </B>Sellers and Buyer agree that the Purchase Price and the Assumed Liabilities (plus other relevant
items) shall be allocated among the Purchased Assets for all purposes (including Tax and financial accounting) as shown on the
allocation schedule (the &ldquo;<B>Allocation Schedule</B>&rdquo;). A draft of the Allocation Schedule shall be prepared by Buyer in
accordance with the methodology set forth on <U>Exhibit&nbsp;D</U> and delivered to Sellers within 60 days following the Closing
Date. If Sellers notifies Buyer in writing that Sellers objects to one or more items reflected in the Allocation Schedule, Sellers
and Buyer shall negotiate in good faith to resolve such dispute; <I>provided, however</I>, that if Sellers and Buyer are unable to
resolve any dispute with respect to the Allocation Schedule within 30 days following the Closing Date, Buyer and Seller shall
appoint by mutual agreement the office of an impartial nationally recognized firm of independent certified public accountants other
than Seller&rsquo;s accountants or Buyer&rsquo;s accountants (the &ldquo;<B>Independent Accountant</B>&rdquo;) who, acting as
experts and not arbitrators, shall determine the Allocation Schedule. The Independent Accountant shall only decide the specific
items under dispute in the Allocation Schedule. The fees and expenses of the Independent Accountant shall be borne on an
item-by-item basis by the party that does not prevail with regard to such item. Buyer and Sellers shall file all Tax returns
(including amended returns and claims for refund) and information reports in a manner consistent with the Allocation Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section&nbsp;2.06 Non-assignable Assets.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
anything to the contrary in this Agreement, and subject to the provisions of this <U>Section&nbsp;2.06</U>, to the extent that the sale,
assignment, transfer, conveyance or delivery, or attempted sale, assignment, transfer, conveyance or delivery, to Buyer of any Purchased
Asset would result in a violation of applicable Law, or would require the consent, authorization, approval or waiver of a Person who is
not a party to this Agreement or an Affiliate of a Party to this Agreement (including any Governmental Authority), and such consent, authorization,
approval or waiver shall not have been obtained prior to the Closing, this Agreement shall not constitute a sale, assignment, transfer,
conveyance or delivery, or an attempted sale, assignment, transfer, conveyance or delivery, thereof; and that the Closing shall occur
notwithstanding the foregoing without any adjustment to the Purchase Price on account thereof. Following the Closing, Sellers and Buyer
shall use commercially reasonable efforts, and shall cooperate with each other, to obtain any such required consent, authorization, approval
or waiver, or any release, substitution or amendment required to assign such Purchased Asset to Buyer so that Buyer shall be solely responsible
for such Liabilities and obligations with respect to such Purchased Asset from and after the Closing Date; <I>provided</I>, <I>however</I>,
that (y)&nbsp;neither Sellers nor Buyer shall be required to pay any consideration therefor, and (x)&nbsp;if any third-party expense is
required to be paid, Buyer shall advance the amount, which amount shall become an Offset Amount and Buyer may offset the same against
any future Milestone Payments payable by Buyer under this Agreement. Once such consent, authorization, approval, waiver, release, substitution
or amendment is obtained, Sellers shall sell, assign, transfer, convey and deliver to Buyer the relevant Purchased Asset to which such
consent, authorization, approval, waiver, release, substitution or amendment relates for no additional consideration. Applicable sales,
transfer and other similar Taxes in connection with such sale, assignment, transfer, conveyance or license shall be paid by Buyer in accordance
with <U>Section&nbsp;6.05</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
the extent that any Purchased Asset and/or Assumed Liability cannot be transferred to Buyer following the Closing pursuant to this <U>Section&nbsp;2.06</U>,
Buyer and Sellers shall (at the expense of the Party incurring such expense, <I>provided </I>that Buyer will advance the amount of
any expense incurred by Sellers, which amount shall become an Offset Amount and Buyer may offset the same any future Milestone
Payments payable by Buyer under this Agreement) use commercially reasonable efforts to enter into such arrangements (such as
subleasing, sublicensing or subcontracting) to provide to the parties the economic and, to the extent permitted under applicable
Law, operational equivalent of the transfer of such Purchased Asset and/or Assumed Liability to Buyer as of the Closing and the
performance by Buyer of its obligations with respect thereto. Buyer shall, as agent or subcontractor for Sellers pay, perform and
discharge fully the Liabilities and obligations of Sellers thereunder from and after the Closing Date. To the extent permitted under
applicable Law, Sellers shall, at Buyer&rsquo;s expense, hold in trust for and pay to Buyer promptly upon receipt thereof, such
Purchased Asset and all income, proceeds and other monies received by Sellers to the extent related to such Purchased Asset in
connection with the arrangements under this <U>Section&nbsp;2.06</U>. Notwithstanding anything herein to the contrary, the
provisions of this <U>Section&nbsp;2.06</U> shall not apply to any consent or approval required under any antitrust, competition or
trade regulation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;III<BR>
CLOSING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;3.01 Closing.
</B>Subject to the terms and conditions of this Agreement, the consummation of the transactions contemplated by this Agreement (the &ldquo;<B>Closing</B>&rdquo;)
shall take place remotely by exchange of documents and signatures (or their electronic counterparts) concurrently with the execution of
this Agreement by the Parties. The date on which the Closing is to occur is herein referred to as the &ldquo;<B>Closing Date</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section&nbsp;3.02 Closing Deliverables.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
the Closing, Sellers shall deliver to Buyer the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Whitehead Letter duly executed by Whitehead and Navitor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>a
bill of sale in the form of <U>Exhibit&nbsp;A</U> hereto (the &ldquo;<B>Bill of Sale</B>&rdquo;) and duly executed by Sellers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>an
assignment and assumption agreement in the form of <U>Exhibit&nbsp;B </U>hereto (the &ldquo;<B>Assignment and Assumption Agreement</B>&rdquo;)
and duly executed by Sellers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>an
assignment of Patents in the form of <U>Exhibit&nbsp;C</U> hereto (the &ldquo;<B>Assignment of Patents</B>&rdquo; and, together with this
Agreement, the Bill of Sale, the Assignment and Assumption Agreement, and the other agreements, instruments and documents required to
be delivered at the Closing, the &ldquo;<B>Transaction Documents</B>&rdquo;), duly executed by Sellers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>letters
to the FDA notifying the FDA of the change in ownership of the Purchased Assets, specifically of those pending Investigational New Drug
Applications Nos. <FONT STYLE="font-size: 10pt">***</FONT>, to Buyer, in form and substance reasonably satisfactory to Buyer, duly executed
by Sellers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vi)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>a
certificate pursuant to Treasury Regulations Section&nbsp;1.1445-2(b)&nbsp;that neither Seller is a foreign person within the meaning
of Section&nbsp;1445 of the Code duly executed by each Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>a
certificate of the Secretary or an Assistant Secretary (or equivalent officer) of each Seller certifying as to (y)&nbsp;resolutions of
the board of directors and stockholders or managers and members of the Sellers (as applicable), duly adopted and in effect, which authorize
the execution, delivery and performance of this Agreement and the other Transaction Documents and the consummation of the transactions
contemplated hereby and thereby, and (z)&nbsp;the names and signatures of the officers of each Seller authorized to sign this Agreement,
the Transaction Documents and the other documents to be delivered hereunder and thereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(viii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>such
other customary instruments of transfer, assumption filings or documents, in form and substance reasonably satisfactory to Buyer, as may
be required to give effect to this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ix)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>possession
and control of the Purchased Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
the Closing, Buyer shall deliver to Sellers the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>a
countersignature to the Assignment and Assumption Agreement with respect to Sellers duly executed by Buyer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>an
Assignment of Patents, duly executed by Buyer; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>a
certificate of the Secretary or Assistant Secretary (or equivalent officer) of Buyer certifying as to (y)&nbsp;the resolutions of the
board of directors of Buyer, duly adopted and in effect, which authorize the execution, delivery and performance of this Agreement and
the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby; and (z)&nbsp;the names and signatures
of the officers of Buyer authorized to sign this Agreement, the Transaction Documents and the other documents to be delivered hereunder
and thereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPRESENTATIONS AND WARRANTIES OF SELLERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in
the Disclosure Schedules, each Seller represents and warrants to Buyer, jointly and severally, that the statements contained in this <U>ARTICLE&nbsp;IV</U>
are true and correct as of the date hereof. The Disclosure Schedules shall be arranged in sections and subsections corresponding to
the numbered and lettered sections and subsections contained in this <U>ARTICLE&nbsp; IV</U>. The disclosures in any section or
subsection of the Disclosure Schedules corresponding to any section or subsection of this <U>ARTICLE&nbsp;IV</U> shall qualify the
representations and warranties made in such section or subsection and other sections and subsections in this <U>ARTICLE&nbsp;IV</U>
if indicated by cross-references to such other sections and subsections or if the applicability of such disclosure to any other
applicable representation or warranty is readily apparent from the text of such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.01 Organization
and Qualification of Sellers. </B>Each Seller is duly organized, validly existing and in good standing under the Laws of the state of
its incorporation or organization. Each Seller is duly licensed or qualified to do business and is in good standing in each jurisdiction
in which the ownership or operation of the Purchased Assets makes such licensing or qualification necessary, except where the failure
to be so licensed, qualified or in good standing would not have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.02 Authority
of Sellers. </B>Each Seller has all necessary corporate or limited liability company power and authority to enter into this Agreement
and the other Transaction Documents to which such Seller is a party, to carry out its obligations hereunder and thereunder, and to consummate
the transactions contemplated hereby and thereby. The execution and delivery by each Seller of this Agreement and any other Transaction
Document to which such Seller is a party, the performance by each Seller of its obligations hereunder and thereunder and the consummation
by each Seller of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the
part of such Seller. This Agreement has been duly executed and delivered by each Seller, and (assuming due authorization, execution and
delivery by Buyer) this Agreement constitutes a legal, valid and binding obligation of each Seller, enforceable against each Seller in
accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar
Laws affecting creditors&rsquo; rights generally and by general principles of equity (regardless of whether enforcement is sought in a
proceeding at Law or in equity). When each other Transaction Document to which each Seller is or will be a party has been duly executed
and delivered by such Seller (assuming due authorization, execution and delivery by each other Party thereto), such Transaction Document
will constitute a legal and binding obligation of such Seller enforceable against it in accordance with its terms, except as such enforceability
may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors&rsquo; rights generally and by
general principles of equity (regardless of whether enforcement is sought in a proceeding at Law or in equity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.03 No Conflicts;
Consents. </B>The execution, delivery and performance by each Seller of this Agreement and the other Transaction Documents to which it
is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a)&nbsp;result in a violation
or breach of any provision of the certificate of incorporation, certificate of formation, or limited liability company agreement, as applicable,
of such Seller; (b)&nbsp;result in a violation or breach of any provision of any Law or Governmental Order applicable to such Seller or
the Purchased Assets; or (c)&nbsp;result in the creation or imposition of any Encumbrances on the Purchased Assets. No consent, approval,
Permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to either
Seller in connection with the execution and delivery of this Agreement or any of the other Transaction Documents and the consummation
of the transactions contemplated hereby and thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.04 Title
to Assets. </B>Sellers have good and valid title to all of the Purchased Assets. All such Purchased Assets are free and clear of Encumbrances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.05
Relevant Contracts. </B>&ldquo;<B>Relevant Contracts</B>&rdquo; means any and all Contracts (including all amendments and
modifications thereto), other than the Whitehead License, to which any of the Sellers is a party and (a)&nbsp;related in any way to,
is relevant to, or restricts in any way, the ability to Exploit the Compound or any Product, (b)&nbsp;that is a collaboration with
any Third Party (other than Buyer) with respect to the development, testing, manufacture, or Exploitation of the Compound, and
(c)&nbsp;involving in any way the Purchased IP. There are no Relevant Contracts. Sellers have delivered to Buyer a true, correct and
complete copy of the Whitehead License. The Whitehead License is in full force and effect, Sellers have complied with all of its
obligations thereunder, and is a valid, binding and enforceable obligation of the Sellers, and, to the Knowledge of the Sellers,
each of the other parties thereto. Neither Seller (i)&nbsp;is (with or without the lapse of time or the giving of notice, or both)
in material breach of the Whitehead License, and to the Knowledge of the Sellers, no other party thereto is in material breach of or
default under the Whitehead License, (ii)&nbsp;has received any written notice regarding any actual or alleged violation or breach
of or default under, the Whitehead License, or (iii)&nbsp;has any Knowledge that any event has occurred that (with or without the
passage of time or giving of notice) would constitute a material breach or default of, or permit termination, modification,
acceleration or cancellation of, the Whitehead License or of any material right or liability thereunder. The Whitehead License has
not been cancelled or otherwise terminated, and neither of the Sellers has received any written notice from any Person regarding any
potential cancellation or termination. Other than the Whitehead License, there are no Contracts (oral or written) that are relevant,
necessary, useful, or convenient to Buyer for the Exploitation of the Compound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section&nbsp;4.06 Intellectual Property.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
 &ldquo;<B>Purchased IP</B>&rdquo; includes (i)&nbsp;all of the Product Intellectual Property, including all Intellectual Property Registrations
relating to the Compound or any Product or the Exploitation thereof (the &ldquo;<B>Product Intellectual Property Registrations</B>&rdquo;),
(ii)&nbsp;all trademarks or tradenames that are Controlled by Sellers and relating to the Compound or any Product, and (iii)&nbsp;all
other Intellectual Property included in the Purchased Assets. None of the Purchased IP is involved in or has been involved in any outstanding
Governmental Order, any interference, re-issue, inter-partes review, post-grant review, reexamination, invalidation, cancellation, opposition
or similar Action. Neither Seller has received any written or, to the Knowledge of the Sellers, threatened Action challenging the validity,
enforceability, scope, inventorship or ownership of any Purchased IP. Section&nbsp;4.06(a)&nbsp;of the Disclosure Schedules sets forth
a complete and accurate list of all Product Intellectual Property Registrations, together with the name of the current owner(s). Sellers
are the sole and exclusive owner of all rights, title and interest in and to each of the Product Intellectual Property Registrations owned
by Sellers free and clear of all Encumbrances, and the ownership of the entire right, title and interest in and to each of the Product
Intellectual Property Registrations owned by Sellers listed in Section&nbsp;4.06(a)&nbsp;of the Disclosure Schedules is recorded before
the applicable patent office or other Governmental Authority solely in the name of either Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Product Intellectual Property Registration is: (A)&nbsp;subsisting; (B)&nbsp;to the Knowledge of the Sellers, valid and enforceable;
and (C)&nbsp;has not expired or been cancelled or abandoned, and each Seller has complied with all requirements of any patent office
or other Governmental Authority applicable to such Seller (including without limitation any disclosure requirements, payment of
filing, examination, renewal and maintenance fees, proofs of working or use, post-registration filing of affidavits of use, and
incontestability and renewal applications). All pending patent applications listed in Section&nbsp;4.06(a)&nbsp;of the Disclosure
Schedules are pending and have not been abandoned and have been and continue to be timely prosecuted. All registered Patents listed
in Section&nbsp;4.06(a)&nbsp;of the Disclosure Schedules have been duly registered or filed with or issued by each appropriate
Governmental Entity in the jurisdiction indicated therein, all related necessary affidavits of continuing use have been timely
filed, and all related necessary renewal and maintenance fees and documents have been timely paid and submitted to continue all such
rights in effect. None of the issued Product Intellectual Property Registrations listed on Section&nbsp;4.06(a)&nbsp;of the
Disclosure Schedules have been declared invalid, in whole or in part, by any Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Sellers
exclusively own or possess all legal rights to all Purchased IP without any conflict with the rights of other Persons. No Seller is bound
by any outstanding judgment, injunction, order or decree related to the use of the Purchased IP, or restricting the use of or the licensing
thereof to any Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Sellers own, have a valid license to use, or otherwise have valid and legally enforceable rights to use all rights necessary for the Development
and Exploitation of the Compound or any Product as currently conducted. To the Knowledge of the Sellers, the Development or Exploitation
of the Compound or any Product (i)&nbsp;does not violate any license, (ii)&nbsp;does not infringe, misappropriate or otherwise violate
any Intellectual Property rights Controlled by any Third Party, and (iii)&nbsp;does not misappropriate any confidential information or
trade secrets Controlled by any Third Party. Neither Seller has received any written charge, complaint, claim, demand, or notice alleging
that Development or Exploitation of the Compound or any Product, or any of the Purchased IP infringes, misappropriates or violates such
Third Party&rsquo;s Intellectual Property rights. To the Knowledge of the Sellers, no Third Party is infringing, misappropriating or otherwise
violating any Purchased IP or either Seller&rsquo;s rights therein or thereto. The Sellers have not brought any Action alleging any infringement,
misappropriation, or other violation of any Purchased IP against any Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Sellers have taken commercially reasonable and industry-standard measures to protect, maintain, and safeguard all confidential information
of the Sellers and all Product Know-How and other trade secrets relating to the Compound or any Product. To the Knowledge of the Sellers,
no confidential information, Product Know-How, or trade secrets relating to the Compound or any Product of either Seller have been disclosed
to any Third Party, except pursuant to appropriate written confidentiality agreements. To the Knowledge of the Sellers, no employee or
consultant of the Sellers has misappropriated, or has been alleged to misappropriate, the Product Know-How or trade secrets relating to
the Compound or any Product of any other Person or either Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Other
than with respect to commercially available software products under standard end-user object code license agreements and except as
set forth on Section&nbsp;4.06(f)&nbsp;of the Disclosure Schedules, there are no outstanding options, licenses, agreements, claims,
encumbrances or shared ownership interests of any kind relating to the Purchased IP, nor is either Seller bound by or a party to any
Contracts of any kind with respect to the Patents, trademarks, service marks, trade names, copyrights, industrial designs, trade
secrets, licenses, information, proprietary rights and processes of any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
the past three years, there has been no unauthorized access, use, intrusion, data breaches, ransom-ware, cybercrime or cyberterrorism
(including by a nation-state or nation state-sponsored threat actor), breach of security, or material failure, breakdown, performance
reduction, or other adverse event affecting any Computer Systems, that has caused or could reasonably be expected to cause any: (i)&nbsp;substantial
disruption of or interruption in or to the use of such Computer Systems; (ii)&nbsp;material loss, destruction, damage, or harm of or to
either Seller or its operations, personnel, property, or other assets; or (iii)&nbsp;material Liability of any kind to either Seller.
Each Seller has taken all reasonable actions, consistent with applicable industry best practices, to protect the integrity and security
of the Computer Systems and the data and other information stored or processed thereon. Each Seller (y)&nbsp;maintains commercially reasonable
backup and data recovery, disaster recovery, and business continuity plans, procedures, and facilities; and (z)&nbsp;tests such plans
and procedures on a regular basis, and such plans and procedures have been proven effective in all material respects upon such testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
current or former employee, contractor, or consultant of either Seller of any of their Affiliates owns any rights in or to any Purchased
IP. Except as set forth on Section&nbsp;4.06(h)&nbsp;of the Disclosure Schedules, each current and former employee, consultant and contractor
of each Seller has assigned to such Seller all Intellectual Property rights he or she owns that are related to the Purchased IP that he,
she or it solely or jointly conceived, reduced to practice, developed or made during the period of his, her or its employment or consulting
relationship with such Seller that (i)&nbsp;relate, at the time of conception, reduction to practice, development, or making of such Intellectual
Property rights, (ii)&nbsp;were developed on any amount of such Seller&rsquo;s time or with the use of any of such Seller&rsquo;s equipment,
supplies, facilities or information or (iii)&nbsp;resulted from the performance of services for such Seller. All moral rights in all Purchased
IP owned or purported to be owned by either Seller have been waived. Each inventor named on the Product Intellectual Property Registrations
listed on Section&nbsp;4.06(a)&nbsp;of the Disclosure Schedules has executed a valid and enforceable agreement assigning their entire
right, title and interest in and to such Product Intellectual Property Registration, and the inventions disclosed therein, to the Sellers.
To the Knowledge of the Sellers, no such inventor has any contractual obligation that precludes any such assignment or otherwise conflict
with the obligations of such inventor under such agreement with the Sellers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
Person who was involved in, or who contributed to, the creation or development of any Purchased IP, has performed services for the government,
university, college, or other educational institution or research center in a manner that would affect the applicable Seller&rsquo;s rights
in the Purchased IP. To the extent applicable, the Sellers are in full compliance with the reporting of inventions, patent filing requirements,
and all other obligations under the Bayh-Dole Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
Products made, used, or sold under any Patent of either Seller have been marked with the proper patent notice and other applicable Intellectual
Property markings and notices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
execution of this Agreement by the Sellers does not conflict with, or result in any violation or breach of, or default under, or give
rise to a right of, or result in termination, cancellation or acceleration of any obligations or to the loss of a benefit under, the Whitehead
License or result in the creation of any Encumbrance in or upon any Purchased IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.07 Legal
Proceedings</B>. Except as set forth on Section&nbsp;4.07 of the Disclosure Schedules, there is no Action of any nature pending, nor has
there been any Action pending in the last three (3)&nbsp;years prior to the date hereof, or, to the Knowledge of the Sellers, threatened
against or by any Seller (a)&nbsp;relating to or affecting the Purchased Assets or the Assumed Liabilities; or (b)&nbsp;that challenges
or seeks to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement. No event has occurred, nor circumstances
exist, that would reasonably be expected to give rise to, or serve as a basis for, any such Action. Section&nbsp;4.07 of the Disclosure
Schedules lists each Action that either Seller has threatened in writing against any other Person in the last three (3)&nbsp;years prior
to the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.08 Governmental
Orders. </B>Except as set forth on Section&nbsp;4.08 of the Disclosure Schedules, as of the date of this Agreement, neither Seller is
subject to or in violation of any material outstanding writ, order, judgment, injunction or decree of any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.09 Legal
Compliance</B>. Sellers are in compliance in all material respects with all Laws applicable to the ownership, use, operation, or Development
of the Purchased Assets. No Seller has received any written notification from any Governmental Authority that there is an Action pending
by such Governmental Authorities or alleging a violation of any Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.10 Permits</B>.
Section&nbsp;4.10 of the Disclosure Schedules lists all Permits included in the Purchased Assets (the &ldquo;<B>Transferred Permits</B>&rdquo;),
including the names of the Permits and their respective dates of issuance and expiration. The Transferred Permits are all of the Permits
required by the FDA or any other comparable Governmental Authority that is responsible for the oversight and enforcement of Healthcare
Laws at the current stage of development for the Compound and any Products, including to permit any Manufacturing, labeling, storing,
testing, research and Development of each Product as currently conducted. Sellers have delivered true and correct copies of the Transferred
Permits to Buyer. The Transferred Permits are valid and in full force and effect, and neither Seller is in default with respect to any
Transferred Permit. All fees and charges with respect to such Transferred Permits as of the date hereof have been paid in full. To the
Knowledge of the Sellers, no event has occurred that, with or without notice or lapse of time or both, would reasonably be expected to
result in the revocation, suspension, non-renewal, modification, lapse, restriction, or limitation of any Transferred Permit. The transactions
contemplated hereby will not result in a default under or a breach or violation of, or adversely affect the rights and benefits afforded
to either Seller by, any Transferred Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section&nbsp;4.11 Privacy Matters</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Sellers have complied in all material respects with all applicable Privacy Requirements. The Sellers have taken the measures
required by Privacy Requirements designed to protect Personal Information collected by the Sellers against any material loss,
damage, unauthorized access, use, modification, and/or disclosure. Each Seller is and has been in material compliance with all Laws
relating to data loss, theft and breach of security notification obligations. To the Knowledge of the Sellers, there has been no
material loss, damage, or unauthorized access to Personal Information owned or collected by the Sellers that has given rise to a
duty to notify any data subject or Governmental Authority. To the Knowledge of the Sellers, no Person has provided any written
notice, made any written claim, or commenced any Action with respect to loss, damage, or unauthorized access and/or use of any
Personal Information collected by the Sellers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Sellers have taken commercially reasonable precautions designed to cause all Computer Systems to be free from any material defect, known
bug, virus or programming, design or documentation error or corruption. All Computer Systems and all software licensed by a Person to
the Sellers and currently used by the Sellers, in each case can be replaced with commercially available, off-the-shelf replacements in
the event such Computer Systems or software, as applicable, becomes unavailable or is no longer supported by the licensor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Seller has in place policies necessary to protect the privacy and security of Personal Information, including policies and procedures
in compliance with all Privacy Requirements, reasonably intended to respond to complaints received alleging violation of applicable privacy
or security standards and to identify and report all breaches of Personal Information in accordance with the relevant Seller&rsquo;s legal
and contractual obligations and have performed a thorough assessment of the potential risks and vulnerabilities to the confidentiality,
integrity, and availability of electronic Personal Information held by such Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
action has been asserted or, to the Knowledge of the Sellers, threatened in a formal notice or commenced against either Seller alleging
non-compliance with HIPAA, a data security violation, or a violation of any Person&rsquo;s privacy, personal information, or data rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
Seller is subject to any contractual requirements, privacy policies or other legal obligations that, following Closing, would prohibit
Buyer from receiving and using any Personal Information included in the Purchased Assets, other than those requirements imposed by Law
or published guidance from a Governmental Authority. None of the Purchased Assets consist of a database that is subject to a registration
or notification requirement with any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section&nbsp;4.12 FDA and Regulatory Matters</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
research, Development, Manufacture, marketing, promotion, offering for sale, sale, importation, use or intended use or other
disposal of any Purchased Asset by the Sellers or by any third party on behalf of the Sellers (other than Buyer) has, and has been
at all times, in compliance with all applicable Healthcare Laws. The Products that are part of the Purchased Assets are, and have,
been Manufactured, researched and Developed by the Sellers or by any third party on behalf of the Sellers (other than Buyer), in
compliance with all applicable Healthcare Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Sellers
have delivered to Buyer true and correct copies or originals of (i)&nbsp;all Permits, certifications, orders, clearances, or exemptions,
granted or pending with the FDA or any other Governmental Authority to research, Develop, or market any Product; (ii)&nbsp;each clinical
trial protocol submitted by either Seller to the FDA or any other Governmental Authority; (iii)&nbsp;all other filings or submissions
made by either Seller pursuant to the FDCA; and (iv)&nbsp;any material correspondence between either Seller and the FDA or any other Governmental
Authority concerning either Seller or a Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
Seller has received any written notice, or to the Knowledge of the Sellers, any oral notification, that the FDA or any other Governmental
Authority responsible for oversight or enforcement of any Healthcare Law, or any institutional review board (or similar body responsible
for oversight of human subjects research) or institutional animal care and use committees (or similar body responsible for oversight of
animal research), has initiated, or threatened to initiate, any Action to restrict or suspend, nonclinical research on or clinical study
of any Product, or to recall, suspend or otherwise restrict the Manufacture of any Product, or in which the Governmental Authority alleges
or asserts a failure to comply, with applicable Healthcare Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>There
are no Actions pending or, to the Knowledge of either Seller, threatened in writing, with respect to any alleged violation by Sellers,
or, to the Knowledge of the Sellers, of any of their respective subcontractors, partners, or collaborations (other than Buyer), of the
FDCA or any other Healthcare Law, and neither Seller nor, to the Knowledge of the Sellers, any of their respective subcontractors, partners
or collaborators, is party to or subject to, nor is any Product subject to, any corporate integrity agreements, monitoring agreements,
consent decrees, deferred prosecution agreements, settlement orders or similar Contracts with or imposed by any Governmental Authority
related to any Healthcare Law, and no such Contract is currently pending, or, or to the Knowledge of the Sellers, threatened. Neither
Seller is a defendant nor named party in any unsealed qui tam or False Claims Act litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
Seller, nor to the Knowledge of the Sellers, any Person engaged by either Seller for contract research or contract Manufacturing of any
Product, nor any partners or collaborators of either Seller with respect to any Product has made an untrue statement of a material fact
or a fraudulent statement to the FDA or any Governmental Authority responsible for enforcement or oversight with respect to Healthcare
Laws, or failed to disclose a material fact required to be disclosed to the FDA or other such Governmental Authority that, at the time
such disclosure was made, would reasonably be expected to provide a basis for the FDA to invoke its policy respecting &ldquo;Fraud, Untrue
Statements of Material Facts, Bribery, and Illegal Gratuities&rdquo; set forth in 56 Fed. Reg. 46191 (September&nbsp;10, 1991), or for
any other Governmental Authority to invoke a similar policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
Seller nor any of their respective current or former members, officers, partners, or employees, nor to Knowledge of the Sellers,
their respective contractors or agents who have provided services relating to any Purchased Asset have been or are currently
suspended, excluded or debarred from any federal contracting or healthcare programs, or threatened in writing, or to the Knowledge
of the Sellers, orally, with or currently subject to an investigation or proceeding that could result in suspension, exclusion or
debarment under state or federal statutes or regulations, or assessed or threatened with assessment of civil monetary penalties.
Neither Seller nor any of their respective current or former stockholders, members, officers, partners, employees, nor to the
Knowledge of the Sellers, the respective contractors or agents who have provided services relating to any Purchased Asset have been
convicted of any crime or engaged in any conduct that has previously caused or would reasonably be expected to result in
(i)&nbsp;disqualification or debarment under 21 U.S.C. Sections 335 or any similar law, rule&nbsp;or regulation of any other
Governmental Authority, or (ii)&nbsp;exclusion under 42 U.S.C. Section&nbsp;1320a-7 or any similar law, rule&nbsp;or regulation of
any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
pre-clinical studies and clinical trials conducted by or on behalf of a Seller (other than by Buyer) with respect to any Product by or
at the direction of either Seller (other than by Buyer) have been conducted in material compliance with all Healthcare Laws, as applicable,
including 21 C.F.R. Parts 11, 50, 54, 56, 58 and 312 and comparable foreign Laws and all applicable Laws governing the privacy of patient
medical records and other personal information and data. Neither Seller has received any notifications or other communications from any
institutional review board, ethics committee, safety monitoring committee or Governmental Authority raising any issues in any jurisdiction
requiring the termination or suspension or investigation of any clinical studies relating to the Purchased Assets conducted by, or on
behalf of, either Seller, or in which either Seller has participated and, to the Knowledge of the Sellers, no such action has been threatened
in writing, or to the Knowledge of the Sellers, orally. Complete and correct copies of all material Regulatory and Clinical Materials,
including scientific and clinical data of either Seller with respect to all Products, have been made available to Buyer. Such Regulatory
and Clinical Materials are complete and correct in all material respects and have been maintained in compliance by the Sellers or on the
behalf of the Sellers (other than by Buyer) with all applicable formal filing and maintenance requirements. Sellers have made available
to Buyer complete and correct copies of all serious adverse event reports, periodic adverse event reports, non-clinical expedited safety
reports, and all other material Governmental Authority communications, documents and other material information submitted by either Seller
to or received by either Seller from any Governmental Authority, including inspection reports, warning letters and similar documents,
relating to the Sellers or any Purchased Asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>[Reserved].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>[Reserved].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Seller owns or has the right to use and access (including the right to make copies of) all material information and data generated
in all development activities and all nonclinical, toxicology and other studies, and clinical studies and trials (together with data
sets associated with such studies) with respect to the Products, in each case, undertaken by or on behalf of such Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Since
the onset of Development of any Product by or on behalf of a Seller until the effective date of the Development Agreement, there has
not been: (i)&nbsp;any suspension, rejection, or refusal of any regulatory application, filing, authorization or approval relating
to any Products; (ii)&nbsp;any clinical hold, suspension, material adverse modification, or termination of any current preclinical
or clinical study, trial or test with respect to any Products; (iii)&nbsp;any adverse safety findings limiting further development
of any Products, or announcements of any of the foregoing; (iv)&nbsp;any production or supply chain disruption materially affecting
the research, testing, development or manufacture of any Products; (v)&nbsp;any public statements, decisions or other pronouncements
made, published or proposed by professional medical organizations, Governmental Authorities or representatives of any of the
foregoing, or any panel or advisory body empowered or appointed thereby, directly relating to any Products; (vi)&nbsp;any increased
incidence or severity of any previously identified side effects (including toxicity) or reports of new side effects, with respect to
any Products; (vii)&nbsp;any determination or development relating to coverage, reimbursement or payor rules&nbsp;or policies
applicable to, or pricing of, any Products; or (viii)&nbsp;the expiry, finding of invalidity or unenforceability or loss of
exclusivity with respect to any Patent, or the abandonment or lapse of any Patent application, or the final refusal by any patent
office of any Patent application, in all cases owned or licensed by either Seller relating to any Purchased Asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.13 No Brokers</B>.
Neither Seller has employed any broker or finder that would result in the obligation of either Seller or Buyer to pay any finder&rsquo;s
fees, brokerage or agent&rsquo;s commissions in connection with the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section&nbsp;4.14 </B>[Reserved].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.15 Full
Disclosure</B>. No representation or warranty by the Sellers in this Agreement and no statement contained in the Disclosure Schedules
to this Agreement, any Transaction Document, or any certificate or other document furnished or to be furnished to Buyer pursuant to this
Agreement contains any untrue statement of a material fact, or omits to state a material fact necessary to make the statements contained
therein, in light of the circumstances in which they are made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;4.16 No Other
Representations and Warranties</B>. Except as expressly set forth in this Agreement and the other Transaction Documents, none of any of
the Sellers or any representative or advisor of the Sellers, or any of the Sellers&rsquo; employees, officers, directors, agents or securityholders
(the &ldquo;<B>Seller Parties</B>&rdquo;), has made or makes any other express or implied representation or warranty, either written or
oral, on behalf of the Sellers, including any representation or warranty as to the accuracy or completeness of any information regarding
the Sellers furnished or made available to Buyer and its Affiliates or representatives or as to the future revenue, profitability or success
of the Purchased Assets, or any representation or warranty arising from statute or otherwise in law, and all such other representations
and warranties are hereby expressly disclaimed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;V</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPRESENTATIONS AND WARRANTIES OF BUYER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in the
Disclosure Schedules, Buyer represents and warrants to Sellers that the statements contained in this <U>ARTICLE&nbsp;V</U> are true and
correct as of the date hereof. The Disclosure Schedules shall be arranged in sections and subsections corresponding to the numbered and
lettered sections and subsections contained in this <U>ARTICLE&nbsp;V</U>. The disclosures in any section or subsection of the Disclosure
Schedules corresponding to any section or subsection of this <U>ARTICLE&nbsp;V</U> shall qualify the representations and warranties made
in such section or subsection and other sections and subsections in this <U>ARTICLE&nbsp;V</U> if indicated by cross-references to such
other sections and subsections or if the applicability of such disclosure to any other applicable representation or warranty is readily
apparent from the text of such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;5.01 Organization
and Authority of Buyer. </B>Buyer is a corporation duly organized, validly existing and in good standing under the Laws of the State of
Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;5.02 Authority
of Buyer. </B>Buyer has all necessary corporate power and authority to enter into this Agreement and the other Transaction Documents to
which Buyer is a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and
thereby. The execution and delivery by Buyer of this Agreement and any other Transaction Document to which Buyer is a party, the performance
by Buyer of its obligations hereunder and thereunder and the consummation by Buyer of the transactions contemplated hereby and thereby
have been duly authorized by all requisite corporate action on the part of Buyer. This Agreement has been duly executed and delivered
by Buyer, and (assuming due authorization, execution and delivery by Sellers) this Agreement constitutes a legal, valid and binding obligation
of Buyer enforceable against Buyer in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium or similar Laws affecting creditors&rsquo; rights generally and by general principles of equity (regardless
of whether enforcement is sought in a proceeding at Law or in equity). When each other Transaction Document to which Buyer is or will
be a party has been duly executed and delivered by Buyer (assuming due authorization, execution and delivery by each other party thereto),
such Transaction Document will constitute a legal and binding obligation of Buyer enforceable against it in accordance with its terms,
except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors&rsquo;
rights generally and by general principles of equity (regardless of whether enforcement is sought in a proceeding at Law or in equity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;5.03 No
Conflicts; Consents. </B>The execution, delivery and performance by Buyer of this Agreement and the other Transaction Documents to
which it is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a)&nbsp;result
in a violation or breach of any provision of the certificate of incorporation or by-laws of Buyer; (b)&nbsp;result in a violation or
breach of any provision of any Law or Governmental Order applicable to Buyer; or (c)&nbsp;require the consent, notice or other
action by any Person under, conflict with, result in a violation or breach of, constitute a default under or result in the
acceleration of any agreement to which Buyer is a party, except in the cases of clauses (b)&nbsp;and (c), where the violation,
breach, conflict, default, acceleration or failure to give notice or obtain consent would not have a Material Adverse Effect on
Buyer&rsquo;s ability to consummate the transactions contemplated hereby. No consent, approval, Permit, Governmental Order,
declaration or filing with, or notice to, any Governmental Authority is required by or with respect to Buyer in connection with the
execution and delivery of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated
hereby and thereby except where the failure to make or obtain such consents, approvals, Permits, Governmental Orders, declarations,
filings, or notices would not have a Material Adverse Effect on Buyer&rsquo;s ability to consummate the transactions contemplated
hereby and thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;5.04 Brokers.
</B>No broker, finder or investment banker is entitled to any brokerage, finder&rsquo;s or other fee or commission in connection with
the transactions contemplated by this Agreement or any other Transaction Document based upon arrangements made by or on behalf of Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;5.05 Legal
Proceedings. </B>There are no Actions pending or, to Buyer&rsquo;s knowledge, threatened against or by Buyer or any of its Affiliates
that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;5.06 Investigation;
No Reliance. </B>Buyer acknowledges and agrees that it has made its own inquiry and investigation into, and, based thereon, has formed
an independent judgment concerning the Sellers, the Purchased Assets and the transactions contemplated by this Agreement and any other
assets, rights or obligations to be transferred hereunder or pursuant hereto. Except for the specific representations and warranties expressly
made by the Sellers in <U>ARTICLE&nbsp;IV</U> or in any Transaction Document, (i)&nbsp;Buyer acknowledges and agrees that the Sellers
and the Seller Parties are not making and have not made any representation or warranty, expressed or implied, at law or in equity, in
respect of the Purchased Assets or any of the Sellers&rsquo; or their Affiliates respective businesses, assets, liabilities, operations,
prospects, or condition (financial or otherwise), including any representation or warranty as to the accuracy or completeness of any information
regarding the Sellers furnished or made available to Buyer and its Affiliates or representatives or as to the future revenue, profitability
or success of the Purchased Assets, or any representation or warranty arising from statute or otherwise in law; and (ii)&nbsp;Buyer specifically
disclaims that it is relying upon or has relied upon any such other representations or warranties that may have been made by any person.
Notwithstanding the foregoing, nothing in this <U>Section&nbsp;5.06</U> shall limit or preclude any claims, rights, Actions or remedies
of Buyer in respect of Fraud, and to set off any Milestone Payments Offset Amounts in respect of Losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;VI<BR>
COVENANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;6.01 Books
and Records</B>. In order to facilitate the resolution of any claims made by or against or incurred by Buyer after the Closing, or for
any other reasonable purpose, for a period of 2 years following the Closing, Sellers shall: (i)&nbsp;retain copies of its records which
relate to the Purchased Assets for periods prior to the Closing; and (ii)&nbsp;upon reasonable notice, afford the Buyer and its Business
Representatives reasonable access (including the right to make, at Buyer&rsquo;s expense, photocopies), during normal business hours,
to such records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;6.02
Public Announcements. </B>Except as otherwise expressly set forth in this <U>Section&nbsp;6.02</U>, no Party shall issue any press
release or other public communications relating to the terms of this Agreement or the transactions contemplated by this Agreement or
use the names of the other Parties directly or indirectly in any media interview, advertisement, news release, press release or
professional or trade publication, or in any print media, whether or not in response to an inquiry, without the prior written
approval of the other Parties. Notwithstanding the foregoing, after the Closing, the Buyer may make such disclosures regarding this
Agreement and the transactions contemplated by this Agreement in its filings with the Securities and Exchange Commission, including
the filing of this Agreement, as it determines in its sole discretion to be necessary or desirable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;6.03 Confidentiality.
</B>From and after the Closing, Sellers shall, and shall cause their Affiliates to, hold, and shall use their commercially reasonable
efforts to cause their respective Business Representatives to hold, in confidence any and all information, whether written or oral, concerning
the Purchased Assets, a Milestone Report, and the negotiation, drafting and contents of the Transaction Documents, except to the extent
that such information (a)&nbsp;is generally available to and known by the public through no fault of such Sellers, any of their Affiliates
or their respective Business Representatives; or (b)&nbsp;is lawfully acquired by such Sellers, any of their Affiliates or their respective
Business Representatives from and after the Closing from sources that are not prohibited from disclosing such information by a legal,
contractual or fiduciary obligation. If Sellers or any of their Affiliates or their respective Business Representatives are compelled
to disclose any information by judicial or administrative process or by other requirements of Law, such Sellers shall promptly notify
Buyer in writing and shall disclose only that portion of such information which Sellers are advised by counsel in writing is legally required
to be disclosed; <I>provided, however</I>, that such Sellers shall use commercially reasonable efforts to obtain an appropriate protective
order or other reasonable assurance that confidential treatment will be accorded such information (at Buyer&rsquo;s expense).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;6.04 Bulk
Sales Laws. </B>The Parties hereby waive compliance with the provisions of any bulk sales, bulk transfer or similar Laws of any jurisdiction
that may otherwise be applicable with respect to the sale of any or all of the Purchased Assets to Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;6.05 Transfer
Taxes. </B>All transfer, documentary, sales, use, stamp, registration, value added, and other such Taxes and fees (including any penalties
and interest) incurred in connection with this Agreement and the Transaction Documents (including any real property transfer Tax and any
other similar Tax) shall be borne and paid by Buyer when due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;6.06 Further
Assurances. </B>Following the Closing, each of the Parties shall, and shall cause their respective Affiliates to, execute and deliver
such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably required to consummate
and make effective the transactions contemplated by this Agreement and the other Transaction Documents. Sellers will provide Buyer with
a reasonable amount of transitional business assistance after the Closing to facilitate the transfer of the Purchased Assets; <I>provided</I>,
that if Sellers will incur any third-party expense to comply with this <U>Section&nbsp;6.06</U>, Buyer will advance the amount of any
expense incurred by Sellers, which amount shall become an Offset Amount and Buyer may offset the same against any future Milestone Payments
payable by Buyer under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section&nbsp;6.07 Non-Competition; Non-Solicitation</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0 0pt 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>For
a period of five (5)&nbsp;years commencing on the Closing Date (the &ldquo;<B>Restricted Period</B>&rdquo;), Sellers shall not, and
shall cause each of <FONT STYLE="font-size: 10pt">***</FONT>, <FONT STYLE="font-size: 10pt">***, and *** (collectively, the
 &ldquo;<B>Restricted Parties</B>&rdquo;) not to, directly or indirectly, (i)&nbsp;engage in or assist any Person in engaging in the
Restricted Business anywhere in the world; (ii)&nbsp;have an interest in any Person that engages directly or indirectly in the
Restricted Business in any capacity, including as a partner, shareholder, member, employee, principal, agent, trustee or consultant;
or (iii)&nbsp;cause, induce or encourage any material actual or prospective client, customer, supplier or licensor of the of the
Sellers relating to the Purchased Assets (including any existing or former client or customer of Sellers and any Person that becomes
a client or customer of the Sellers in respect of the Purchased Assets after the Closing), or any other Person who has a material
business relationship with the Sellers in respect of the Purchased Assets, to terminate or modify any such actual or prospective
relationship. Notwithstanding the foregoing, Sellers may own, directly or indirectly, solely as an investment, securities of any
Person engaged in a Restricted Business that is traded on any national securities exchange if Sellers are not a controlling Person
of, or a member of a group which controls, such Person and does not, directly or indirectly, own five percent (5%) or more of any
class of securities of such Person. Notwithstanding the foregoing, nothing contained in this <U>Section&nbsp;6.07</U> shall in any
manner restrict or apply to any equityholder, officer, director, manager, employee, or contractor of the Sellers (for the avoidance
of doubt, other than the Restricted Parties or Navitor Parent in its capacity as an equityholder of Navitor).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Sellers
acknowledge that a breach or threatened breach of this <U>Section&nbsp;6.07 </U>would give rise to irreparable harm to Buyer, for which
monetary damages would not be an adequate remedy, and hereby agrees that in the event of a breach or a threatened breach by Sellers of
any such obligations, Buyer shall, in addition to any and all other rights and remedies that may be available to it in respect of such
breach, be entitled to equitable relief, including a temporary restraining order, an injunction, specific performance and any other relief
that may be available from a court of competent jurisdiction (without any requirement to post bond).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Sellers
acknowledge that the restrictions contained in this <U>Section&nbsp;6.07</U> are reasonable and necessary to protect the legitimate
interests of Buyer and constitute a material inducement to Buyer to enter into this Agreement and consummate the transactions
contemplated by this Agreement. In the event that any covenant contained in this <U>Section&nbsp;6.07</U> should ever be adjudicated
to exceed the time, geographic, product or service or other limitations permitted by applicable Law in any jurisdiction, then any
court is expressly empowered to reform such covenant, and such covenant shall be deemed reformed, in such jurisdiction to the
maximum time, geographic, product or service or other limitations permitted by applicable Law. The covenants contained in this <U>Section&nbsp;6.07</U>
and each provision hereof are severable and distinct covenants and provisions. The invalidity or unenforceability of any such
covenant or provision as written shall not invalidate or render unenforceable the remaining covenants or provisions hereof, and any
such invalidity or unenforceability in any jurisdiction shall not invalidate or render unenforceable such covenant or provision in
any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;6.08 Whitehead
Letter</B>. In connection with the transactions contemplated by this Agreement, Sellers shall procure from Whitehead an acknowledgement
and estoppel letter, substantially in the form of <U>Exhibit&nbsp;E</U> (the &ldquo;<B>Whitehead Letter</B>&rdquo;). For the avoidance
of doubt, nothing in this <U>Section&nbsp;6.08</U> shall obligate the Buyer to take any action or pay any sum pursuant to the Whitehead
License and Buyer shall have no liability to the Sellers with respect to any action or omission of Buyer with respect to the Whitehead
License.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;VII</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEMNIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;7.01 Survival.
</B>Subject to the limitations and other provisions of this Agreement, the representations and warranties contained herein shall survive
the Closing and shall remain in full force and effect until the date that is eighteen (18) months from the Closing Date; <I>provided,
</I>that the representations and warranties in (i)&nbsp;<U>Section&nbsp;4.01</U>, <U>Section&nbsp;4.02</U>, <U>Section&nbsp;4.03(a)</U>,
<U>Section&nbsp;4.04</U>, <U>Section&nbsp;4.06</U>, <U>Section&nbsp;4.13</U>, <U>Section&nbsp;5.01</U>, <U>Section&nbsp;5.02</U>, and
<U>Section&nbsp;5.04</U> shall survive indefinitely, and (ii)&nbsp;<U>Section&nbsp;4.11</U> and <U>Section&nbsp;4.12</U> shall survive
for six years. None of the covenants or other agreements contained in this Agreement shall survive the Closing Date other than those which
by their terms contemplate performance after the Closing Date, and each such surviving covenant and agreement shall survive the Closing
for the period contemplated by its terms. Notwithstanding the foregoing, any claims asserted in good faith with reasonable specificity
(to the extent known at such time) and in writing by notice from the non-breaching Party to the breaching Party prior to the expiration
date of the applicable survival period shall not thereafter be barred by the expiration of such survival period and such claims shall
survive until finally resolved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;7.02 Indemnification
By Sellers. </B>Subject to the other terms and conditions of this <U>ARTICLE&nbsp;VII</U>, from and after Closing, Sellers shall, jointly
and severally, indemnify Buyer against, and shall hold Buyer and its Affiliates, successors and assigns (collectively, &ldquo;<B>Buyer
Indemnitees</B>&rdquo;) harmless from and against, any and all Losses incurred or sustained by, or imposed upon, any Buyer Indemnitee
based upon, arising out of, with respect to or by reason of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
inaccuracy in or breach of any of the representations or warranties of either Seller or both Sellers contained in this Agreement, the
Transaction Documents, or in any certificate or instrument delivered by or on behalf of Sellers pursuant to this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
breach or non-fulfillment of any covenant, agreement or obligation to be performed by either Seller or both Sellers pursuant to this Agreement
or the Transaction Documents or any certificate or instrument delivered by or on behalf of the Sellers pursuant to this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Fraud
by any Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
Excluded Asset or any Excluded Liability;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
claim made by any stockholder or member of any Seller against any Buyer Indemnitee directly or indirectly related to this Agreement
or the Transaction Documents and consummation of the transactions contemplated hereby or thereby (other than claims made to enforce
rights under this Agreement or the Transaction Documents);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
ownership, Development, or use of the Purchased Assets on or prior to the Closing Date; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
claim made by Whitehead, Howard Hughes Medical Institute or any of their respective current and former trustees, officers, employees,
and agents for indemnification pursuant to the Whitehead Letter or the Whitehead License (other than claims arising out of the personal
injury, death, or property damage resulting from the development, manufacture, packaging, labeling, distribution, sale, or use of any
Product offered by Buyer on or after the Closing Date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;7.03 Indemnification
By Buyer. </B>Subject to the other terms and conditions of this <U>ARTICLE&nbsp;VII</U>, from and after Closing, Buyer shall indemnify
Sellers and their respective Affiliates, successors, and permitted assigns (collectively, &ldquo;<B>Seller Indemnitees</B>&rdquo;) against,
and shall hold Sellers harmless from and against, any and all Losses incurred or sustained by, or imposed upon, any Seller Indemnitee
based upon, arising out of, with respect to or by reason of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
inaccuracy in or breach of any of the representations or warranties of Buyer contained in this Agreement, the Transaction Documents, or
in any certificate or instrument delivered by or on behalf of the Buyer pursuant to this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
breach or non-fulfillment of any covenant, agreement or obligation to be performed by the Buyer pursuant to this Agreement or the Transaction
Documents or any certificate or instrument delivered by or on behalf of the Buyer pursuant to this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
Assumed Liability;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Fraud
by Buyer; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
ownership, Development, or use of the Purchased Assets after the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;7.04 Certain
Limitations. </B>The Party making a claim under this <U>ARTICLE&nbsp;VII </U>is referred to as the &ldquo;<B>Indemnified Party</B>&rdquo;,
and the Party against whom such claims are asserted under this <U>ARTICLE&nbsp;VII</U> is referred to as the &ldquo;<B>Indemnifying Party</B>&rdquo;.
The indemnification provided for in <U>Section&nbsp;7.02</U> and <U>Section&nbsp;7.03</U> shall be subject to the following limitations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
aggregate amount of all Losses for which the Indemnifying Party shall be liable pursuant to <U>Section&nbsp;7.02</U> or <U>Section&nbsp;7.03</U>,
as the case may be, shall not exceed the Purchase Price paid (or due and payable) pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
the foregoing, the limitations set forth in <U>Section&nbsp;7.04(a)&nbsp;</U>shall not apply to Losses based upon, arising out of, with
respect to or by reason of Fraud against the party that committed such Fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>For
purposes of this <U>ARTICLE&nbsp;VII</U>, (including for purposes of determining the existence of any inaccuracy in, or breach of,
any representation or warranty and for calculating the amount of any Loss with respect thereto), any inaccuracy in or breach of any
representation or warranty shall be determined without regard to any materiality, Material Adverse Effect or other similar
qualification contained in or otherwise applicable to such representation or warranty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section&nbsp;7.05 Indemnification Procedures.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
any Indemnified Party receives notice of the assertion or commencement of any Action made or brought by any Person who is not a party
to this Agreement or an Affiliate of a Party to this Agreement or a Business Representative of the foregoing (a &ldquo;<B>Third-Party
Claim</B>&rdquo;) against such Indemnified Party with respect to which the Indemnifying Party is obligated to provide indemnification
under this Agreement, the Indemnified Party shall give the Indemnifying Party prompt written notice thereof. The failure to give such
prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations, except and only to the extent
that the Indemnifying Party forfeits rights or defenses or is otherwise disadvantaged by reason of such failure. Such notice by the Indemnified
Party shall describe the Third-Party Claim in reasonable detail, shall include copies of all material written evidence thereof and shall
indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party. The
Indemnifying Party shall have the right to participate in, or by giving written notice to the Indemnified Party, to assume the defense
of any Third-Party Claim at the Indemnifying Party&rsquo;s expense and by the Indemnifying Party&rsquo;s own counsel, and the Indemnified
Party shall cooperate in good faith in such defense. In the event that the Indemnifying Party assumes the defense of any Third-Party Claim,
subject to <U>Section&nbsp; 7.05(a)</U>, it shall have the right to take such action as it deems necessary to avoid, dispute, defend,
appeal or make counterclaims pertaining to any such Third-Party Claim in the name and on behalf of the Indemnified Party. The Indemnified
Party shall have the right, at its own cost and expense, to participate in the defense of any Third-Party Claim with counsel selected
by it subject to the Indemnifying Party&rsquo;s right to control the defense thereof. If the Indemnifying Party elects not to compromise
or defend such Third-Party Claim or fails to promptly notify the Indemnified Party in writing of its election to defend as provided in
this Agreement, the Indemnified Party may, subject to <U>Section&nbsp;7.05(b)</U>, pay, compromise, defend such Third-Party Claim and
seek indemnification for any and all Losses based upon, arising from or relating to such Third Party Claim. Sellers and Buyer shall cooperate
with each other in all reasonable respects in connection with the defense of any Third-Party Claim, including making available (subject
to the provisions of <U>Section&nbsp; 6.03</U>) records relating to such Third-Party Claim and furnishing, without expense (other than
reimbursement of actual out-of-pocket expenses) to the defending Party, management employees of the non-defending Party as may be reasonably
necessary for the preparation of the defense of such Third-Party Claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
any other provision of this Agreement, neither the Indemnifying Party nor the Indemnified Party, as the case may be, shall enter
into settlement of any Third-Party Claim without the prior written consent of the other (which consent shall not be unreasonably
withheld, conditioned or delayed), except as provided in this <U>Section&nbsp;7.05(b)</U>. If the Indemnifying Party has assumed the
defense pursuant to <U>Section&nbsp; 7.05(a)</U>&nbsp;and a firm offer is made to settle a Third-Party Claim without leading to
Liability or the creation of a financial or other obligation on the part of the Indemnified Party and provides, in customary form,
for the unconditional release of each Indemnified Party from all Liabilities and obligations in connection with such Third-Party
Claim, the Indemnifying Party may settle the Third-Party Claim upon such terms. If the Indemnified Party is maintaining the defense
pursuant to <U>Section&nbsp;7.05(a)</U>, it shall not agree to any settlement without the written consent of the Indemnifying Party
(which consent shall not be unreasonably withheld, conditioned or delayed).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
claim by an Indemnified Party on account of a Loss which does not result from a Third-Party Claim (a &ldquo;<B>Direct
Claim</B>&rdquo;) shall be asserted by the Indemnified Party giving the Indemnifying Party prompt written notice thereof. The
failure to give such prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations,
except and only to the extent that the Indemnifying Party forfeits rights or defenses or is otherwise disadvantaged by reason of
such failure. Such notice by the Indemnified Party shall describe the Direct Claim in reasonable detail, shall include copies of all
material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or
may be sustained by the Indemnified Party. The Indemnifying Party shall have thirty (30) days after its receipt of such notice to
respond in writing to such Direct Claim. During such thirty-day period, the Indemnified Party shall allow the Indemnifying Party and
its professional advisors to investigate the matter or circumstance alleged to give rise to the Direct Claim, and whether and to
what extent any amount is payable in respect of the Direct Claim and the Indemnified Party shall assist the Indemnifying
Party&rsquo;s investigation by giving such information and assistance (including access to the Indemnified Party&rsquo;s premises
and personnel and the right to examine and copy any accounts, documents or records) as the Indemnifying Party or any of its
professional advisors may reasonably request. If the Indemnifying Party does not so respond within such thirty-day period, the
Indemnifying Party shall be deemed to have rejected such claim, in which case the Indemnified Party shall be free to pursue such
remedies as may be available to the Indemnified Party on the terms and subject to the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;7.06
Payments; Deductions. </B>Notwithstanding anything to the contrary contained in this Agreement, the Parties agree that with respect
to Losses pursuant to this <U>ARTICLE&nbsp;VII</U> Buyer may (a)&nbsp;deduct any Losses for which any Buyer Indemnitee is entitled
to be indemnified under this Agreement against any Milestone Payment not yet paid to the Sellers (the &ldquo;<B>Offset
Amount</B>&rdquo;), (b)&nbsp;recover against any Milestone Payments previously made, or (c)&nbsp;receive any insurance proceeds
received, realized, or recovered by or on behalf of any Seller in respect of any Loss, for which Sellers shall be obligated to use
commercially reasonable efforts to seek to recover from any insurance policies the Sellers may have to the extent covered by such
policies (<I>provided </I>that Sellers shall not be obligated to litigate with any insurance providers; provided further that Buyer
shall have the right, but not the obligation, to pursue, in Sellers&rsquo; name or otherwise, any claims against such insurance
providers, and Sellers shall cooperate (at the cost and expense of Buyer) with Buyer in such efforts).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;7.07 Tax Treatment
of Indemnification Payments. </B>All indemnification payments made under this Agreement shall be treated by the parties as an adjustment
to the Purchase Price for Tax purposes, unless otherwise required by Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;7.08 Effect
of Investigation. </B>The representations, warranties and covenants of the Indemnifying Party, and the Indemnified Party&rsquo;s right
to indemnification with respect thereto, shall not be affected or deemed waived by reason of any investigation made by or on behalf of
the Indemnified Party (including by any of its Representatives) or by reason of the fact that the Indemnified Party or any of its Representatives
knew or should have known that any such representation or warranty is, was or might be inaccurate, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;7.09 Exclusive
Remedies. </B>Subject to <U>Section&nbsp;8.12</U>, the Parties acknowledge and agree that from and after Closing their sole and exclusive
remedy with respect to any and all claims (other than claims arising from Fraud against the party that committed such Fraud) for any breach
of any representation, warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject matter of this
Agreement or the transactions contemplated hereby, shall be pursuant to the indemnification provisions set forth in this <U>ARTICLE&nbsp;VII</U>.
In furtherance of the foregoing, except with respect to <U>Section&nbsp;8.12</U>, each Party hereby waives, from and after Closing, to
the fullest extent permitted under Law, any and all rights, claims and causes of action for any breach of any representation, warranty,
covenant, agreement or obligation set forth herein or otherwise relating to the Transaction Documents it may have against the other Parties
and their Affiliates and each of their respective Business Representatives arising under or based upon any Law, except pursuant to the
indemnification provisions set forth in this <U>ARTICLE&nbsp;VII</U>. Nothing in this <U>Section&nbsp;7.09</U> shall limit any Person&rsquo;s
right to seek and obtain any equitable relief to which any Person shall be entitled pursuant to <U>Section&nbsp;8.12</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;VIII</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.01 Expenses.
</B>Except as otherwise expressly provided herein (including <U>Section&nbsp;6.05</U> hereof), all costs and expenses, including, without
limitation, fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the
transactions contemplated hereby shall be paid by the Party incurring such costs and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.02 Notices.
</B>Any notices, demands and communications to a Party hereunder shall be in writing an shall be deemed to have been duly given and received
(a)&nbsp;if delivered personally, as of the date received, (b)&nbsp;if delivered by certified mail /return receipt requested, three (3)&nbsp;Business
Days after being mailed, (c)&nbsp;if delivered by a nationally recognized overnight delivery service, two (2)&nbsp;Business Days after
being entrusted to such delivery service, or (d)&nbsp;if sent via electronic mail, as of the date received, to such Party at its address
set forth below (or such other address as it may from time to time designate in writing to the other Parties):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to Buyer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Supernus Pharmaceuticals,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: CEO&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">9715 Key West Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Rockville, MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email: *** with a copy (which shall not constitute notice)
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Saul Ewing LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">1919 Pennsylvania Avenue NW, Suite&nbsp;550</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Washington, DC 20006-3434</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: Mark A. Gruhin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email: ***</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to Sellers:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Navitor Pharmaceuticals,&nbsp;Inc.<BR>
Attention: Thomas E. Hughes, PhD<BR>
6 Liberty Square, PMB #***<BR>
Boston, MA 02109</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email: ***</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Goodwin Procter LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: Kathleen Kean; Danielle Lauzon</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">100 Northern Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Boston, MA 02210</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">***; ***</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.03 Interpretation.
</B>For purposes of this Agreement, (a)&nbsp;the words &ldquo;include,&rdquo; &ldquo;includes&rdquo; and &ldquo;including&rdquo; shall
be deemed to be followed by the words &ldquo;without limitation;&rdquo; (b)&nbsp;the word &ldquo;or&rdquo; is not exclusive; and (c)&nbsp;the
words &ldquo;herein,&rdquo; &ldquo;hereof,&rdquo; &ldquo;hereby,&rdquo; &ldquo;hereto,&rdquo; and &ldquo;hereunder&rdquo; refer to this
Agreement as a whole. Unless the context otherwise requires, references herein: (x)&nbsp;to Articles, Sections, Disclosure Schedules and
Exhibits mean the Articles and Sections of, and Disclosure Schedules and Exhibits attached to, this Agreement; (y)&nbsp;to an agreement,
instrument or other document means such agreement, instrument or other document as amended, supplemented and modified from time to time
to the extent permitted by the provisions thereof and (z)&nbsp;to a statute means such statute as amended from time to time and includes
any successor legislation thereto and any regulations promulgated thereunder. This Agreement shall be construed without regard to any
presumption or rule&nbsp;requiring construction or interpretation against the Party drafting an instrument or causing any instrument to
be drafted. The Disclosure Schedules and Exhibits referred to herein shall be construed with, and as an integral part of, this Agreement
to the same extent as if they were set forth verbatim herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.04 Headings.
</B>The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.05 Severability.
</B>If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or
unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision
in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable, the Parties
shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a
mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest
extent possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.06 Entire
Agreement. </B>This Agreement and the other Transaction Documents constitute the sole and entire agreement of the parties to this Agreement
with respect to the subject matter contained herein and therein, and supersede all prior and contemporaneous representations, warranties,
understandings and agreements, both written and oral, with respect to such subject matter, including, without limitation, that certain
Development and Option Agreement, dated April&nbsp;21, 2020, by and between Navitor and Buyer, that certain Binding Memorandum of Understanding,
dated May&nbsp;5, 2025, by and between Navitor and Buyer, and Letter of Intent, dated May&nbsp;1, 2024. In the event of any inconsistency
between the statements in the body of this Agreement and those in the other Transaction Documents, the Exhibits, Schedules and Disclosure
Schedules (other than an exception expressly set forth as such in the Disclosure Schedules), the statements in the body of this Agreement
will control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.07 Successors
and Assigns. </B>This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors and
permitted assigns. Subject to <U>Section&nbsp;2.04</U>, no Party may assign its rights or obligations hereunder without the prior written
consent of the other Parties, except that Buyer may make such an assignment (by merger or otherwise) without Sellers&rsquo; consent to
(i)&nbsp;any Affiliate of Buyer, or (ii)&nbsp;any Third Party successor-in-interest or purchaser of all or substantially all of the business
or assets of Buyer. The rights and obligations of the Parties under this Agreement will inure to the benefit of and be binding upon its
respective successors and permitted assigns of the assigning Party, whether so expressed or not. No assignment shall relieve the assigning
Party of any of its obligations hereunder. Notwithstanding the foregoing, following the Closing, Navitor may dissolve or merge with and
into Navitor Parent or enter into any similar arrangement or transaction, <I>provided </I>that Navitor Parent shall remain liable for
the obligations of Navitor under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.08 No Third-Party
Beneficiaries. </B>Except as provided in <U>ARTICLE&nbsp;VII</U>, this Agreement is for the sole benefit of the Parties and their respective
successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person or entity
any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.09
Amendment and Modification; Waiver. </B>This Agreement may only be amended, modified, or supplemented by an agreement in writing
signed by each Party. No waiver by any Party of any of the provisions hereof shall be effective unless explicitly set forth in
writing and signed by the Party so waiving. No waiver by any Party shall operate or be construed as a waiver in respect of any
failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether
occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power, or privilege
arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any
right, remedy, power, or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right,
remedy, power, or privilege.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.10 Governing
Law; Submission to Jurisdiction. </B>This Agreement, and all claims or causes of action (whether in contract or tort) that may be based
upon, arise out of or relate to this Agreement, or the negotiation, execution or performance of this Agreement (including any claim or
cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this Agreement or
as an inducement to enter into this Agreement) shall be governed by and construed in accordance with the laws of the State of Delaware,
without regard to conflicts of laws principles. Any proceeding arising out of or relating to this Agreement shall be brought exclusively
in the state and federal courts located in the State of Delaware. This provision may be filed with any court as written evidence of the
knowing and voluntary irrevocable agreement between the parties to waive any objections to jurisdiction, to venue or to convenience of
forum. Each of the Parties (a)&nbsp;shall submit itself to the personal jurisdiction of the state and federal courts located in the State
of Delaware in the event any dispute arises out of this Agreement, (b)&nbsp;will not attempt to deny or defeat such personal jurisdiction
by motion or other request for leave from any such court, and (c)&nbsp;except as set forth below, shall not bring any action relating
to this Agreement in any court other than the state or federal courts within the State of Delaware, as described above. Each of the Parties
agrees that service of any process, summons, notice or document by U.S. registered mail to the respective addresses set forth in this
Agreement shall, be effective service of process for any suit or proceeding in connection with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.11 Waiver
of Jury Trial. </B>EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY&nbsp;ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE
COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY&nbsp;HAVE TO A TRIAL
BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT AND ANY OF THE TRANSACTIONS CONTEMPLATED
HEREBY OR THEREBY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.12 Specific
Performance. </B>The Parties agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance
with the terms hereof and that the Parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy
to which they are entitled at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section&nbsp;8.13 Counterparts.
</B>This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed
to be one and the same agreement. A signed copy of this Agreement delivered by e-mail or other means of electronic transmission shall
be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties
have caused this Agreement to be executed as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">BUYER:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Supernus Pharmaceuticals,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/ Jack A. Khattar</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Jack A. Khattar</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">President, Chief Executive Officer and Secretary</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">SELLERS:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Navitor Pharmaceuticals, LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Thomas E.
    Hughes, PhD</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Thomas E. Hughes, PhD</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Navitor Pharmaceuticals,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Thomas E.
    Hughes, PhD</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Thomas E. Hughes, PhD</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>Signature Page&nbsp;to Asset Purchase Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>supn-20260401.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaqAWbOdzZR+aYkxtmB/bWnqzyIiEj/o0ii86902sbkH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:supn="http://supernus.com/20260401" elementFormDefault="qualified" targetNamespace="http://supernus.com/20260401">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://supernus.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="supn-20260401_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="supn-20260401_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>supn-20260401_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>supn-20260401_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="supn-20260401.xsd#Cover" roleURI="http://supernus.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://supernus.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 01, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  01,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Supernus
Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001356576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-2590184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9715
    Key West Ave<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">838-2500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SUPN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tm2611273d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://supernus.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>supn-20260401.xsd</File>
    <File>supn-20260401_lab.xml</File>
    <File>supn-20260401_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2611273d1_8k.htm">tm2611273d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2611273d1_8k.htm": {
   "nsprefix": "supn",
   "nsuri": "http://supernus.com/20260401",
   "dts": {
    "schema": {
     "local": [
      "supn-20260401.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "supn-20260401_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "supn-20260401_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2611273d1_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://supernus.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-04-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2611273d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-04-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2611273d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://supernus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001104659-26-040497-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-040497-xbrl.zip
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MZZ'*+,86141W;&'0)E/AIN 4_]"A [/0$[7:A3F$YUP_"A8@0=M*EW-BN5R
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M6.KLIFR/V?K^+* + I0><\9=VU+> L73#'1)\R3?R\?I;K:;%>&6QID25VQ
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M8 PE8;ILG_BZ,QOL^VGS;^PO^PY6L^5_4$L#!!0    ( "R+AUQ_E+9321<
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M+LC:DT.)8"P06N:86<RE)FE9,)>ODKAZOI17-*Y75U97/%]3ENT)^PI6 Z)
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ME5])6/HMI<0W&!7%>P2_$%,E=1<2;#W\+"-RI6TCK:5$<1V^)9M$JKGUOQ[
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MD$%IS:%^WN[.8&W0=@/C/G01FEYO>(NS#E#04*/UO+(UZY!6UX/P#Y+E-D%
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MI[W,.;NE@06128? H.Z<+!2T=22MJ2IQ4'O:TO&PZ"!O G5,ML?N3L_X<-V
MCLG0N8=4 ;V3[I85L72$O" ,V]EHIM>=5YFPF_@S,ATZ).-5B1Z3UP%F88N7
M9X6IID0&B-R,;RNW99;6OZK"]"\OM^US.GS49!S>F\DX?7//+9@/TEM!'"'D
ML=_=L4P<RW5R 1M&V'TGRH1R'*5I0I)A27?T*04!&J:!"G$.V?Q#!9ODHP8I
MV--7S\,Q[:<H3VS2W@"T)SIW70BS62[@DNS9&AF?/&,-R\&:F:IGNK:M]D5/
MBU/!'=-7.!3]GA]EU09$B[8?</"W[7DN;#&SO.P41SPSW*)$R2P*,[]"^3RY
MFF!%R2QQ8R^G5)BVU49%4?:) VJS#$RZ7.\:DBT(I:\"9-M*F^ZZ@IFHMZ>Z
M^9:OFJ-WY<02)JW*3464)73W"I T#T7T=)>V\;QF>\%:L5@J!.IUL4GVS,'E
M 6?7,G#XD0^.<A.P&U5UIF!TJ7A,N1#%1];LYSP6_BKB70I^%]4Y[H<<):NZ
MW<B\+'>[X42(#3RF8+] C5*3AN,=5=5;2?K2Q:.LZ0-*W:LZAA^FP<&FRVD-
MI?]9HZR<W.W*1T4QR%8RT:CQ"M<A?,2>>>?KO7B;PJ"P"G.B[R0KJ7$A"?^Z
M%]5T2K-O(V!<.VICL!/):4MAEH,B2,NV*R=GCES&A9+]3M-,_W5/K#PRWUFX
M>2G4C3Z@*Q-BI2W1A"]O9:>E>"RK)%K[7*Z1RJE::G8^0'$WT-F(J;UN:VWT
MGAV-EML8)>N[&(FL<F34:;X04:!_D+@P"D+TAPBR=FY*->8B(N4[1(GVA,:G
MX[86U+N!,-05[0MF,-MW)C&SVLK1,RR4RP@?]]M8D?K0OVJH9+V"BGI:Q<1L
MB.AE[9!=;8%=S&O8:)("(A39W(C"0FK%WK['ML, S<"0WQ.@'CR (FY)$%#&
MVT]DYP]E/-)@H\N9,4-W>$["AMN)JY]=DVO;A%M9JC(7R@WS)_=WL79WAMI%
M!I'M4HTQWOBDA]R?6"G]0GKZUMKB*K0#N2LD%!Z4C^@[4CXFZ\0 $JN0$7%=
M.<Y]Z_)5/03V8G)$NZ?9$>X0J:1SA^MDP *:'.GCO7'G.V&'B3?4"L=7*I9>
M*\%L_%>E8=_Q G,16M3P'!+'Z1C?"'*H!W'DM8/S=P6)PQ8+WF8QTA^_X!CI
MCU]CI']YB5BLY23Q,]3K2M)S&SK\AW]:%&C5.]SEG$ERV^9V/RK5<R];8IT9
M6 _L^C[K&APTJR*\(_U:7!&U^FDHJOU1T^GMDD9L$39ZK#VDIXZ/+P3&"1NG
MV+(2(N"#4DN?R;Z1-L5BLL(PS:4_(F#$W%.9/.R+UV?'AT*'S'T1&RY5\R"K
MF4$Q?][,V.BZE\V'43D7K9U0RV(%Q52M9\V#PI27\"$\3Z9P2G,9GR@76Y5N
M@=\1][1:#;;[PA""B):341+V4BE7>*<DJ0R!RAKICPL:$T QZ&>F#% 6PN2K
MR*6L 2S*3 Z2H^6:\H3[C8W AF)F$E_AJI61,:6$?B23 +_.[.Y4EH%6R]E[
M]8Q:X=@P3R>$EGTH#AOIF#!\?KOMYPL;#AL/M.2XO>CIOE;Y,,O."C358&?Y
MU(5>0U=>2*REII;%9<ZQ!:ED!3@J:O2<32!+=)M9& QQ8/M>PS*.I$Q#9#["
MH>RM:P&V[P?(C\*>5>)S(,<7\-?3!#RXU4*<EJX,_T+$9B8<94*\A/NAW)XC
MMZ:\SNM*?1<&>66SN1!3SS/;8-K,\FZ6^H9V>R0NA3(+-UKFQ!^Y*YC-"&,M
M)U.N/K#OJ&Q/:<#LI' _88/BXG*@6A&<<)%M80=Q#C4:(D0],WJ5+-R6P+5=
MF%@&:QZP]E[HJ3X-^%B/ROZ:59N]"%A.:(;A&]Z[K>,/C'6'CE0,A)!-Q_M=
M:UFY^KQY;6<2VO8S3MCRS#R0HY0[A']XFO)[LCJW/SVW8AH"$^-Y->[ZR-7W
M[%G\^.#A(YH*9"@^\\3MOZ[RUI!Q.TE><EKK@WV2[PX>_K#EHO%!JB68(#GQ
M!DYH@;;368)$QPF2.@W4AI:ZZN\\USO']<U$<TBX4G [K]!);F1JE;&'W)'\
M22K1[0E9D>T-#$D_HE-MDF6D'^ZSO+)IHS.7$<F2Y^2LWS#=B2_C"HMMW?WB
M="\>^2HC!Z:JEUNW!^_[(J\;L$5H4H/.P_Y[_8:1R$L]X7?Z(8UO<8XV#Y/@
M'DM3\[^ZPC9JQQT>/0K(G^Q=Y!!8-Y C<L&*\#9H2M^VV?A*.VC@5&T@VB?O
MKO)1KEQ +[9<KC>+%QX^_((#AH</OT8,_VR%*DM,;_OLEZ.SB]/CER?RN--3
M*)8__Z%O?C\[_O7H_"0Y>O4\.3]Z>?))'WN7IQ%[RCW V.Z.P^(QS9G&(@2+
M=I#@W<]]L247YIEZYNIPK%?@SW27[6U# &GJ3&2QI1%(2S4*PO6YUF5DT(P<
M5!-3Y-<"!0B(^L2^EKO8H(X  /0)3)$K;S,FI[*V#M1)2?;:B%W 1FB]D=;1
M']E6<K5PZS*-@=(D:L<;V[V))R9XWY$IJAN0-DGI$&)X4@PY@&K;W5G"^.U_
MI<[^=&1OM*A>GH$A#(J TX$JX+375>OT#7W9,.*%K8DE3*%M <J_>^[JP))S
M'/U=<0^)<>^0/9M7LVDS@;(XY%G0_@]PA.PF_(K!B$RV(:$>Q=&-@2% FRW$
M9ZJ:NVV%G_&_"VY,:2OVM&D: $,(SES+_1LZHN>L9)H%<&?X 8SEC*,X$T:+
MY4(@@=PT$[+;+GY"'Z@X($D:E'))7%7%8)Z\%_GI&BY=96J:4OE".)P3MQ_L
M/<V1]X9U5'NQ=AKJ!?Z5</M3R_$*Y*YKH7?_-,<=4FKSC%^H30%Z%D4-WKLY
MOD/R:I[C$!\(J*%""P7>V0?J61CVO5N%.^11YE7PS3XC,]8B7V^R&B3>N4"3
MN>-QZ[I.P!97%@/]D>W*X(/AN7$<J]HR(JC8]25)'#T2*.:]6^([9##F)=:U
MH?FVJ=M9EA<A1W!4K;!A237S)=ZWI;JZXZ5"<0(G\$/]-\3=ML6AP(\+*CR2
MX/7$.[P22'@=<YST*]]"5J=5M6VI^O_F'4A6&E3!0L<Q>[)J-(3'-9:>2_UL
MU>[N1%T)DFP,K@PVF#GJ8<D(M$L HA/V2@Y1Z)4.=BKC%;@/DK]JK;L(A%.M
MR)V&OQ&X?/ K"61P"VF9,E]8L30_/</=3O)RX>#^06)IM;/K*I]8ZIU)U8W:
M=&EU7)=F_& I4:%.\M'%"6VJL]-__'IQ3K)S].H?I\]>GB1OSEZ_.3F[^+>\
M\W^_>OVO![^^_E<"XB5^>8T6H;&"F=KV:8//V9>Y\;.L.L]VH""IT#R"GFN#
M=\$\FGG;.Z^B!F:VL?7 2#AW=6_WY6->\ Z0HI?*K,<57TZ0@D\_)O07AN@R
M?J#?F=Q)8YXMT/2X1KF(A/KR1N .256"YI0[V@2CL;K3;U3!<'M!6-HL]A+!
M= 6AR.0YHZ;61NP&IFDYJU56*JC19 :=T]-DN64ZGJ-WW]T)WW"X9WIXQ=Z1
M+5;45[,U?_V#9@DBFB9[SX9_BZK$^,?:I7V<U^-N)F$480]R+=JY?[NJ1_,N
M;UIE:F5UF$M+%FC.P8E/I$2'0Q<HN.2[[^X4V5S8XEH2?OQZ1%.+6$U7"-VF
M)"CE;5&/)]4?R*60D@GX9%SYR?(4' ]- ?<ZO\ZKPB+]N20LM7>6CN;00) 1
MDG)ALIUR[,<6:%D+3&<H3::6<BF<1#]5=3B');^_I(.69HM+/_>>KUMW;X7'
MY\'*TV*%3!_L[O3.YX%-$.]M"*O;WPO'UFDA3J-""X5Y57J[.4#,A*0&I*$<
M2"8^F_F1J4:UI,BQ@[K75>I3(G!U+.D9^0$-HYER=>$$&,P*Y75\0 _-RNZ.
MP"GIE@L^N?1-9*9[]]SBPV+#?.[AEYS//?R:S]TV*^5;=Y:#VXH."#%%CB0B
MGT\LW;NMVNV?_+&.<N0' N)0XV4V+PQ.D](D>X=Z04R#*A:!,'EK!T_'>"ED
MSW%'8'ZF9>F#S!LV:FHC)X)H%(OK]J7Y9!&(F9S/;+Y1/J Y+AF'&]]Y=V?I
MUEQ:[4KV9VBC(VZF[?M';_F [S]#B*[%2[M.6WO0GT#W!%W(W55OY*J(0K]W
MJO26*KI4%H"V% AS83U6J(!P7K ='LVFU?'=7('M-*B<#!$Y8*=:9FZKACD;
MY 8IY?3Z(F@4/O F\;#BU.W7_.NGBW_\_>]_W]WA18RW@VXX-;#:F\H5O"1[
MCZ+M)YRUN77@0:P1%W#:HYR=.[<C)V8&&['.;"D[[1-/+>R8'1S'\#+3K2M6
ME?"!W:E-AY_D6LBAE?4!7XION<[6!M,+P+:%:VE*4BX/]?5L(=+NSO-LH8P%
M\23-N4"#[E:BU-;)OL"O_7ZX=Z'5.\PP>WG5Y7>+(3S'-FXB*ZSL*WSP!,37
M&RU[LFK5P^7F2'[>NGH+J_I6#XR%PP_MWLG&'69M8]G '!\Y,H]/M^18Q&"U
MATK/IO /O;9RX4&2BGNWWG>8,_;KO6(1@A-#>4)6L7JO?P=Z4*+/W&.S$!$B
MB0B0N  %368,FJ=S*(Q'U-,'?)'L_8&Q[G]RE72[@ 9SL\G[Z^O?._&]RW3\
M[@X$BY8(__$VF.8+<6[A"UJ=H[*$1?Z*+*NEOICO9\1(A"\6'G"O9Q+*D[;Q
M_+!I7M*1E3-#OFL"9AVX@)GI&#6SDZQ._@W@9FX+6W&5=TM03\*EL&H5?044
M?'HY4@?QSY"GW9U5NNBOE*?=G74"=1_SXG<)8?@J5&:;.PQL&"E^]"5'BA]]
MC13?::0XJOL@HW7.[3&%<C#,_@V$#SE'Y'=FV/M;<T\Q9<9!<BI>'\<6?7PH
M8(7DJ #W7F"C5QL-ZGT1*7J;S\DH]@^%'A$]$7ZJ$5;-<S+)AP]UL?:8="9=
M%Q?=W2EILGH/"LD\4OD+ YJ;27"A0YX,L8Q8I97:H+0E +!0 '<?M$F7EW!/
M[HTH6KEL$09\^9VD8?M$B4CPT?)@M5%-;\A.M>[N7(3H  $:,+LHK>_R=,]H
M%",C+>3I-G/RO+JL=# 'U\N6!6IE0W)]L5DFM'3"*F+' "P$W,1+5XLD/2,E
M+RD  9< WT1J&>HG%P;GJ- /!9'Q\ BRKTNOY3 N!]%R((-Z'-(PGMGV B8Y
MF4Z9(13991E9?TAK"[F1R=$R?_F@O:JK[O**3NK+_0@F(>@(^F 9+='/-H]Z
MR=A-QJ^[W+C7V=VQ[Q-)1U"&,>W9"V$JVT).\L978@\R"/IQ66)GNV-7-;C1
MO+80H=P>1D?N2W)6DK+2HKF@Q5XZG)D"Z,--4YA*<IHNON]-U@@L3M@9IUVQ
MQ;;,>QPIKZH6"\?@02V2@3UYR3*BU,9MK;3$\8JG/K'(S,& JH6PA@"H&SNO
M;VSF3760)8*R( YF I8&7*)4?&HO5"\V/\%+2#]EXPC%BN"SFM&#6BMT(2O6
M$O651Z4NCS -]R@M#.W*J*D3"\O>HC\+#H*C;\:8G6A$ <'[PJOT /S9,];=
M7:OIE*E%AK:@YD'_1X?C2(4%D625K]W9-B%K/^?I5 73E4&/%28>,O>E;_(+
M03Q-/#:+E%$$-^I967Q*J3YSX%;UNGY\F$S@8*D &3F?5#[40UJ0AX3L<C"C
MI*"R'&3+-S5:-Y901IQ4L\Z8T-W9 @4:Q&7-#'W5#;-2+V>&G>@V9$34EGDV
MGW%=7FL8\4E[43AI;TR!K./AHWT()0D)F6YYA7W&+5FL!1*$6&5XX&N'O=]'
M:$7-[GL$V+;;(-S)SNT+@'^K1EC5@0+C**M+43Z/;<S6-Y3I]V)P]T&+98O[
M]V9F>*,<KBB/!"=PN^]([27](%"Y8!"M4/QC_I^'3.@6GZO#9L1? :#"9"@P
M'#_4T0#[V9 &\W5E"9*B*KDC3S[MWYL^^H/IZ1DPP06;?42"5V1G0G$>XZ*/
M6F8:0W2=FPG \]<P^^Z.BB2W4D3-=UQ6KLQ.BB^O)#FMY%O"E4W*!A!'DAA0
MR9<H,KYVYIWS413A ?(6)D0IY6T$5@*F8WK 1,Y_YZK8R0O;YJFPEQ"YPE-9
M7E6<2%!!UD:\/-\XZCOI11FK?)TI,J/[1V)4L)"N,8N C*M!(FVBVOULZ2GR
M*N'LN7=J>LQ1K.'IEC0CV?PJ-(^&K",UIB/O0MG@!\ YMUA Y-7<8@)]B GK
M; :K6E=,#PUN4G4T%?T#6QR[):,O@/^X644@;0]@50FV21U$DEV3\L5;8S,K
MS'Z=M :FXL+FGM7DX!?;OT6<DT\BS<)+U!?GVESGAB%$/ "$[XJE^=SB@WO#
MJ-OC+SGJ]OAKU&W;\)E/=G>."A"'6D<T;N:FA2/!S@[.S<##C'[D-,( YCS9
MFQ>P%U1966,E;\VLV??^0R9C0E2(#+O+X:(03E47A5<C@4UUD;WC8?@T .D[
MN"KTY3X?3J3<2Z7>Y18L=@X:9?_HFR+!-%F"D)XQDDQJ,L6MSAVXWK^?GJX3
MKT6Y-\X8M=99U$=E9MJK:E(5U>4B"-%4Y1(AV7,$9\+C6MQ0[V.RG?^=VOD!
M8M/;P,@$M[3FI][UE39:IG&C9$M??D>+[\P@:3G$Q2*E.HGHU()EI66>2ALB
M6Z,U,#6I/Z/ZO$ EV2LMFV+T<VX6-<UX=N"5D[Z[-GIFY<V\:\VM13OY-!D0
MZ!J^HIZ&."?EQK"/];Z#8:&A1=:9?KQNIB,'S1=&R!O3%,P9"@GIF'7<CSES
MT2G<I0*.T8+9\AF<;XBX[192++AL_[(DA8TM4#.G.)3!W+!&8'H\K.O$ 15E
M=V1,5XO-R5SFE@LU!*SYR_J)N/#+)5H2_^PC=UF$Y+VYJE+V%^$1D1B8=ZBJ
M;+0X"ZVE2-2Y3Q?X6E@R'&A[U5H<)(@D#S]<[\&XG(D9YUHQ:8L+52=IA-#*
MP&H!ED>!_)='C-&7C:]U6SL&4@ATH)?,!)Z5\N0'H\4#_#<990T\OH4&BUU/
M[DEEQ HD70([T,HG.I0YZQ)W.%@2,UN?!I8'UJ#0EF0T=S7W^PL\4Z5WU.\4
M?YOE,U&^M+%I>O8UJQ"V29-V5%S5I=AWAOLWK8NOKIK&[;7P0J[4@9/TN^15
M53Z0.!GK$2V6WF["N<\.E=[S:7%<N#AO<EN8ETN]XBK8.#W$/QA(?GPGY>IQ
M';(S?\"C+I3?-'?:9J['@6<K+_5L7G M8-;2]ISC8.0[).]W ^NUN?9\/6(Z
MS4.&%991:60 @GB9W?" ["]03V_L;#8R=6%C,-\+CW^5<71 8/C,IPYE3D[J
M[@XK;JNUJGZBA3,F/E6K=UAQ<:B6Z&V'.U;MVS7VX>#^T/ET[8_=)Z5\UE0Z
M%N*(M'6PP0&>]H?G[Q 4N&;K%I;9OU:*1OFQTB&]5I]Z2MS0_-"S#S!57J35
M82)'M,=9@ GT@DU##EC^.,#D=+,# 'G!@ &4+MM@EIF]XW:G01HPB.YHWB^J
M'*U OY!9 TU*2/'PU+>=3+0=V965[<FM@KV[XZ0CM:D]11JEPDF')<ZE4MIU
M;_3W9]9@+)B&>6+GQ6_>IEJ.+"&!4A6&7QVIX"8?%4KGS#<+_2G.) >AN^$@
M4^_ITZ740628WAX-TTXW+F%41LW-89?4_3<*9T;*;A>]&D"6F&FEU*![[_3>
M^=3GTK2KIEI7K&+"^\*SRO))C[1@<IW98+_ $VS"2,$*=HAHDH&-]YHS4\F1
M?.M]!"3Y)&NE6A^7"[\2'T/)M$-GH:'\H,6X.7=O*.MUD+S&.-<IKZ 'J97-
M0:%DZ?52F3=.FZWE;EW2*X/4K?SVUG<?DFS%=]![L([[F!?I[RYIIH2=4%8.
MQI(5L20=(-]@SS9I<N)9:0.:)<N5Q4U6<$+VZ1@%;+.Q]M7V)X&;3\(8NOB)
M]_ U'#S F+_M7;P^N\*P"P4 A&9;9#"IY))@?$.KV(]:+=#F2=/);4!#Z+;#
ML(<?XY#6F96[.ZL<M#T]MJV^LSE$5H)D#RGM!(NI7A,E^A,HZ^!XX<SXLCYD
M[F2&U5B]RK>6\)3/%'\RG3F@*AWP;$-=N;^)F=##4DCQ)?@_+A4/O"<?H1"[
M&T'[L&7BFFLIOP?]/5;B$8X><G8LRJ;/+:\>UHJNK69<^SGI>PR"+(1)UV]C
MO;LC-OA<55A6A&W'=-V="K/IUHTEV,EJYB(25DXU6+N[HQ0^+!L>52EY_-46
MAG1(B(!HTAGB4BW\8/:JFC6WE?$^<1!W"E;FH&E7%!+R6&?LA!@=#$1F]1;K
MYB"Y6+<H[!]$CE&?M*3MQ;W<SD-3*W8[ZZX1!"6#'K)@_BW8-2X%4ULYU3-S
M8%DY3&/[>#&IL9F$+>1G59G[5G#AQEU-]C@H0D.LQ*PIPGT3[,A56NT@60G(
M$F:IOK^>JA1N[H^'Q#6T9 L+@G+X(-]5WEN?NO&X,389&5@I;HX\-ZTR(M5L
M*TR,:SM,'Y(<;/&)O&'N\=LO.??X[=?<X]WU^CC]^=D9/?'XY>OSTU?_V.Z(
MZ$?D4Q\?/#RT1\T!0):;<>Y9/1<$*FWHK9O-0K1QB/]D!AU$B$2?<X(@#IC%
M*1@=5YASL1&7%C0SW)Z==-ZL8I3=:.$[HC+9I/9'D\@+8MS<19=1*2W3=07T
MT0$HM-EG\)Q@S!2#J>>1&7>N(7MO[)KN4+YBR:TP)J4*JTCMJ9Y+XA'1+/Q;
MSY?:>$-=FY8MS08;!)B2 YV3[97+=>D'M)[S-HZXZ]SKX'/(/AS>=4KAJ!7_
M<$5WF\'PA_/YMIUQZ-"YZ7V//+^[&6=+K\_4FDRZ8J%J012:OR+H.[?M6_3P
M_>(B^5^Z#+Z$=Y1+;0RB6ZZ_>25(@3ZTY(BM;>V%USM6GNE]>KV]]Q4&V%M1
MW5GW;@W_FD6TJU>&N4;Q#N'QS_DT]4B16U;U68)E'5[5H_CV1_[V[HR.#8DO
M:;6O[W"Q@=#C#J+-;<M[O&;3'@W=,.SRJK&KL"<U++3=G9Z-&N[^U&+^;I,<
MVZ;36#)U^P57!S3DDWM+T]N=09X'#+L!RJW?G"Y^U]NZ_.ZG7XK@_C5R&XMO
MP4<["8XZ0&#E8TSAPL;+\8EEA11W@P2[NBGI5U?YW(6\EWA!(Q9XO@HTX\!8
MX<[H@T5S<6F#J9C5YW5W21(LT3UQH5Y5X$;?D.'(0RZX#L'QG;L.96%EE% ;
M<M!S$?PN$C62XWLK:W_MB;B[HXA&@(:CU,L%UJ2K';\7+WOD/!T>''[[[9,'
MC_9&KOJ1-$J<T89;F3$H AG]N8)<E+#D*N@0SA'I\.9T:Q=QKR9F6=<P8$&>
MLL4RL&&(\<F7'&)\\C7$N"W*Y\_2/L/ZQE59H?(,T$,%MC5 O$(/^6\0+HL2
M>P!RH_!J&BH"Q6<O! L-->:0-HQ,[VS@4 (7HPJ87ZX)K U.'(W2M=7X+7)2
M2LU/4TU+K5_.N*O\4B\.M'KQ^2]K&V63BH%H2A\B[-LN(ZS #F.S[!K72QT:
M3=)@07IQ*>+9LP@';39WS6V!44Y@^<BH)>^07^/?O?)R_+[,9F8IMJGWUD5J
M^HOD7ERR:3@9>G%<F9'U;R-O[.U<RT=NK5N?UW1OP']N\6'Q@7OVDV]:W:V2
M5-6^'C0(&C_#@[VG@85VF)[ EQ8B7MX\;H$^W/;+F">"G9<0M':)0DTEM%^"
MO7X.Y'7OZS^_^RM-PWE%_@*S>TN0@M/-5;'*K]CB+&\0++]#,-52L#R$6@:A
M\I 4ZC,,EF\FR7=*PJA)-G=>N9JTVR,P2RAANUI+W@FO[CT[:NXFY%YR6<9R
MV&T@_"23?@\U_U\<)[_=2G]/$UUTW6KC7(#1H8$NH*8! ]V3%[V'A9U\E($M
MBOM36-C)+0;VT\T,; Z7]"ULQ2G>:ELGG]"T%M,@L*VW>^]M"+OYYR=-_J]\
MZ-G)F[.3\Y-7%T<7IZ]?G2='KYXG_SHZ.SMZ=7%Z<IZ\?I&<G[Q\>7)VOMU8
MA/=09"?2E31K(M)$V5[/\V9,IA'.8UO32@\,W49'T2*"JAT)F\!1^ /%WX5V
MID/-#6+< :%?P&B,C9CY3JR"EEP2@]]IBE#A3@Z/Y:^L:VZ@Y9Q<1M?8DJV+
M%2\2$#0('%1:7!G5"M8A,DY+A%V>+ ]?V2'RH+I.\@.H<5M]D]O>,)%75)20
M&[;4'Z/P2[&L0';Z.]L7'WS/_LA[]TGZMUDY[SIC:)N52Z,CIDAS'#WVC7U;
M=Y+*B7&=PX:?&92PK)JVV\0AGUJJ,;$YQC4Y2@\8,X6H9>, PK<\1TB)&"&L
M82-!G%N(NE\/QU'87O50UO&$2%FFM.E$W!W\23EVPQR4&670- 5[<^!!6^S#
M;1A&_^Y+#J-_]S6,OE6HUF^!:GU=7V:E%N^)M?3_L$K+/7.0^I!"&702''BY
M^I65W ,UB&1;YQ/V>K2-KMJ]3._B*@9\0VBT\;4*FT\_CGWGTNV\JN=5[51'
M%8ST(!D:AY;I,6>C*.9<S,Q)Y:G*>$#-\I@L:^H?79TWI#]E0J+F)D'RNO85
M/:LB3@F:/&I_]:CLZ#_1!)<&5'5<)Z%-T6]P6DM\)<L+TGN<9.?:8?>*:?""
MW.NX]S92\._JWK/D-YI;\$4F1Q.R.QHF7B9AV&*5^G&2_<AS!VCR=H40HP.$
ML!'I.B16[K3T<Y;C)"U\T6 UFS-#:'6CL?O,M96*Z])BQ\;Y(FL]M:C*-DI2
M<X4T0Q7&=(C2KNO:I1*N53F%U/(Y.@=0DSKOX_R)'>;AW4$)\:*7\%Z1"')6
M0OCRNSOV[3=X>=3DQ>5LO:=N.B.#+C'C-I9>X_UF*2":D " =WAQ8:$E2PU)
M52!I*@>6M@ROZPP@&0MF/YI0U[HD#C/%1&'Q^VA^C!,AT!)@\^^5;T?+N[L3
MKJ]22?;6U;-B8)T*<XG2;SX&^&&C7!227Y->MHT>"8:AL6&+4<ONHT488E##
M,G/-A=.:F:I:=S?9K4K@;;<QO<8H*]_6W;P=+QB5!CJP$O\F#RDX85(0G8&4
M*N^XB[N6E',Y)]K50'GBO<8TRT O-UHU:(FP+TTI[IW,PL)^ -*1<IS/M5L.
M1(%&N2?T3@4.*#2SOQ)\GKZ++?57BEYX/UQ/AUI!/F-;G*-Z#L@=]P^2?UV9
M,F#-&-0W?L>9^#RM:D]>KC0OP_*F"-%0X,+-N[FL+:L2&;;2Q@C><5_[9 R]
M"PKOBR)F:6%Q7".'X5"'Q#!OX^+^]Q.^W9U/+'W)!PK?[LZGE;[D-N&[KU;%
MXX1\F>.JG)(=UC9/T22"2U+5KKC8,(J[T6&YL:60@V<S."0_5; WA=W,1;B(
M8RCW_D^TI3UB99F B@E*X*9A SLJ=:G\=7#0.'@?6?II_UO'/I>N-\>R (4<
M0EU2-O^"C?XT<8# %11::U\ 'ZC 1U15K^NX\-_%6>PBUV)Q]=V$I[C3WGAI
M1#Q1- P[I'PFW;C]*$Y*$H51G7%41UL/+:6](;">JL5RL^SNO.'B^'3@'2"W
M8U(V[LG:4!FJC]? 47BG:PB[),"C8(C10@Z4.#<I0,S='7?,+]&TM*OMS>4]
MX_M$?4@VQ*4LWLLBOJ]Z[ENZ=5N(XVD%*20,9AN7/4[,AEA[+7[!L<!B-0H#
MU)"#_ 0-,[5.71^F EW[Z"ZAD&_Q=&\8__O^2X[_??\U_K=M^_P)FGDHW]>Q
MDKGH5O>%-LM7A!5%0,@WRKLA;";NLGXO%,?WU8AS.:LF+@[6!":^Z&ZF*882
M">I))?J5>MLGT/A6-WE32+U==[2*&M?DT0VSMZ1L.CG.,YQIS'_;M#4LO.!B
M"3X$O#LG[^9%E6N)TG"OL#2):P]X:..J*+*1#6SBG!..I@ON*27NSEXP!>IV
M#[%43\*V+ZWAB&L*.' 'D&)7&WX;'6AD!]H!:T\\9W_DY36Y)!H/==,4:?+3
M-QP(0@N1&LWQDB$)B@Z*B+=<80"<LDQ]OA*CT,YI.)CG;EF75E_"4$L?:U 7
M_$()^RV\^A9O$8V'GX/(J;2%D>.*G#JR <)>*;WH&2\>'W6I\R;Y$8'?&'N7
M@52F$6O4?Y?536$FE_T^'B2-UN[T-DS 026,3*_B"A;7KH0&N,=OI+86 H2X
M39'-E6*,U$BB+3HNI9$O?2KF'$L*J<RK?0YZSVRXV%O"*[:B!A;7OA:DQ+^,
M\^9UR0:>!6-Y8J89;&&?+!AXNN^I@O"$8TEBR=4V06JNBH]K66:Q/80HEI;?
M(-\]8/^S3<CDJ\%(TE5#@1F?1\/!@_R<.'HZZ5>*"YC9@O<%DVX.+!Y"@4V3
M74;KUU^[?0WW1Z&/I5GU[P%"*C2%8A<@B3H1ABHYY; ;;6[O"HQAAQ6.:GC%
M7'!Z1'P4-PKMO5<'GIO?8*NV]%6F5,,<=]*'2\;#-V"UX[=M4&V!5^]8N$T^
ME%QL89F.(WFA9:@ ZL.;Q'-0A_-WD+R^_>@*56=P5%:U$A?+L/957FK/R)FB
MBZQ+%G6-(5W'"\EDE66N\3S+72A[9IWRWV)[>ATIRK?@9#\E6[8 ,0VV,1VW
MZ"FP^!Q843XG3O8+**"@Y#HT D(;4,P\;M2BZB_T ;4QWN"*A6WC\)O!BU#B
MF3>MJ"%F!L;N\\SPJSJU#FV!5J!0_<+YM8.,GQ^5F(>=/YEQ"01SM.AO.83.
M?PE TNWF8ZE3*&(NOXS[B6WT6IK$R</GVBJ8X>'K\K@V+4-!HM(L^^RG;^2$
MADDHOZYJGP8(/V<SO&L]>?]06 D7Y7!!%8J$H/>#O&E@!_+G3 +-9(=H&98F
M\ZII'UP"+^0^JHUYEX6-<]D@LY'#0#.#<M,&S#@F:4/H1V/1U#TK:N7Q4-6W
MFVWT!R)U!F VN3]*WNF[\M)6P_,XZ=2#B1<E"=*D(7.7IP!V0>4!!F&I?$QK
M"Q-\224Z1V<=_LWV5V*G(W$&-[MN,$80="WR1KI6%\7ZS1OOBV5>"0$'NZBO
M;4>)]]IK]IV3H!#&*R%'%YOZ'4ELPXWN<+4=C:0W4@TU";0$*,-&8KABB8;V
MZGL,GY\45>X/1*,PB# B%3!>](D-8"W4VFWW_4>\N[/QD$,U@J63'?EAXL&^
M,))=N"U'621H'82UYUS=X#H5J26V*@JL=/>J>*PX1%MOBZV0#:-Z/WS)4;T?
MOD;UML52O,/JP1-VES=7MZ1I?DKVCE0E 7<L>,&GR=XS&S&[[=#U(),@!/-4
M  E[QX$?#@_2O)MS*@K._9(SF8WH-U5I/4C3@X<MQXLTL^6*C#E+&"I&-CG6
M:L;5F<(@:FHC 9SVS#0+M@BQU^%(4E!2:Q7:[HZD[0!1" PF.H'-C4(B9AG.
MHI(STNAOQOS3U50P %7]5N&*';Q6-L7J< $U*XB7IS>>@,./?]EI4 AA)$Z?
MD5&H#K\8N3J @*UG7])"EN)')S*\XL,.MMT=?[+!Q+ /P#@X$.A""TX _'?R
MN186YV5G6^4B",/-RJM&$# R>)D;#G):'B\9,X?3/NPT[B')@D=(5M9*)++#
M,*,]W"OH<]VSQ4] CNT.Y!#L&I0-M,*TFJJL2]S< R3C!=?Y85POQVSLH&6F
M6!#MSAJ^WSJA3&*RL/[=I1.'UBXHV[O '&7-,DTWDM,HT!A7@Q<[/3I_[V,O
MJDA6MZ_N[LYMR\L)=Y9O#3 S[AC6L.!JX!BEC!_L)]QE/;?8AOJPHVQ\=T>9
M\TJ<$P*(^PT[OTHZP&(EV#(5*TU[1[YSV&!KK)@A[QKI#Q%A%IP;AQT%L.%Q
M>",$ -@IZ;G8-'^32TG\Y.4?73FV$)D)8TT@4O!>@JX >&C7#+KY4=++>JQZ
MK091'(*='0(.H6C9CPS\WDG@Y([#;JX#[PV]G8+XQ>*QW8AH_CM-//AH.%_I
M+2,64L U@R25%UDLL?>K XULH\?/?8)1[*IUX>1^^ V6DZ,'!RUZ-^;C\N+V
M:$KTY'X.TT%U5CW812%=*U5)[DB'FF(Y=^2NR\LI&N_0E[.\"0[1>([U;I*V
M'3XJ=$;C8%\OR[L4R'/#Z#W<*I!\HBF(L">K;VO1<*7[+0_=// E#5NDAT:!
M4SF5%K' A\TXF^FQ8)Q$4^60M>L6[Q:A<2WY!H.1NCI-?WDXV*JKTNAY'[RS
M:^BR;JTVD,NRBI+T'!OE$4G:/1R2VLY.9G9W-+^H^<?HO<!+$*Z)&Z_=J4I\
M+YM2DL 746K+VK*U8'3Q!(U#VI71Z*M,H')8Q2-6A*6<1G%#T?Z +3RZ+UOW
M[0PP6W(&\ *CF4.YLC.6A!8G]#KUX@$;"6"FF#%'IA3]TD*WC(5@$SMC\QYV
M<S8UEQTNEJ:;PVK&Z=PP81$&B+%K'OQ:W00ES+%6VC"[<?LV1$9XY3C3I0&E
M+A'SOD-9BE2&%KL8]'#OU R*%+N6!81\I:%"=RHV> MVD!UA\F;:"-#4:F$,
M'P*,9BV8\V0@]1TK3%'>+I5C,1 TS/BZ-(JBNS5>-Z/*(K5Z2GT1F&;:^^KO
MWJF1Z1VHD5B;,"R!#^=R"4@6:90,'>>EO68U;6\X:B)+9YN#.=UBRLD#,B#I
MQ)!..&.PX%K;U$NRS>=(F<SNCF?6&/2<I[?'17H8BM IJN::BM)Q($$3D)!+
MBWM.P870>68YX["*2^+8+(V+[KW-!S*TL0]5<ARFIS+8@5, ?- PFS$E'OT1
M/F0(Z.<HI7Q^.:7-5U_#^-(_94=RMCEE!)W-ENFQ $TY,6#<L1=C,7C_AO,5
M*5-1!$*?I,8(U[*@_ >>\-!^WN+MNV$^Y\<O.9_SX]=\SK:<&Y=W9WZ>*NO1
M/&M:1C>89&&RVNE>9SJ0 N[*H,89B,&F224R05JT[AJIA<O:3*&(F"04V52S
M!SA@2%DM1G0 U8INY+]H"]1TQV8&@(U+A\"=3225\4#9(FK]6]@C'G!7]4H@
ME8!D)$S6NI\&V%*$[6L&7C!ULN(3E6I!+GP[X:A+4+('T!%.P=A+RI1+01"=
MOBX3*A$64 <J@/-%TYI9HS1/G$_*.F6I&#-N,V"8'4E/X+&-8V<<HBD7/_F@
MAC+3PF;DQJJH)E5'C8/%F#K]2'W&*/;'F:;^X)X&P1 W)73N@L0084'[YI-L
MEET:-1ZE/0D_@$[4Z-3#0'"L68Z,)E5N_=(4<JH(^,O/9% +ER\/Q3>\#4]*
M5T-F#<?=G3ZS@SA-DG;POM)8Q\3-Q9O6$6<&.3GK2]&*T Z8<X]@!GQX3TH2
M!S3?E[7-;EG9BD)4X40[O CO!^\KA1&=IJTTQV//6<W(]'E/'#VA]>B:5>[A
M[LZ(#I]N+MD4/!HP#Q32I7!E,J25@H^X:M@2IMC\#KWBO,C*1MO43N!7RJ73
M;*R-?/O\@&Q!L<3Q3R6&Z'\.$S#3=JQD*F6T&.J4NI\DO5]X%PREC,9F<P 5
MRF6A/>18;*A&6O+R+;5&8HM-E \[*:[N[J1X19O?0;L8=SQ#[;AZIFGB>T1;
MK'+@I?:TQC0(_>5U<C1%DEGB>S=:9.33>*+9HMC4[@Z0<4,L?H.^QM4FO@8?
M&_8%6=H'WM"^DB.BYA=F+= '$TC/IZ!1LR6=7XE^U5>^,N*I&)F,$!X>IGBB
M0)T<.:B!;N3G>6LA6?2'I2-$'T^._P(?0*><W,SJO-26&8E.8A8[VHLV341C
MS"OF0+W"[KWRVE]FR :!=98X2"Q^%'T 5XLU;S@34@R11V5;J6T&)3404QGS
MW((:]&@>'+8DR7CD;Q6QP$\+)YNA*^%LA]F!&Q@\P1P(!B.;@::Y1R+A(K>V
M5,.E^_3T5?D>^@F ''.-S#8=3B*(G]>M<KJ'@?_PJ)3"<1J>(]'KT<:JM\CH
MSYA7!O"%&9<?^,T5)3.QK11KB$.I0[&^2MS(>!#BJEC930;9TJ/+HES949VX
MLO7-\^Z[.YLGWE?!*IJ +F<81A1TVY,-J^*.=K@,[%1 P2W(3JETWOCE/)Q4
MIHEQ!B[4Z&$9NM4MI]7NSB;!0AZ+FWY;GV2U%5=#^>HUWH-SL@@$U\\LF?A]
MV+$N3(G9_#9(6%3BPUHZ*_+N\1I+XEO&Y.7AB]VW8_HN>.673VL-N]Y<5;0U
M(WP_JTE\SE*1CSK9Y=JV.B"CF(0)ON4$4<KBI0J(.6 #W8-[73H("RF[KD1U
M:,,N&8ICS660U$Z@V_FY'.B7^C8=!;A%LQK'LR5=X[JWLK2'B)3%9=J"(\8Q
M#Z;:&*S5/T5=+)Z6- "FC6QG1)<2J8VK0!7(H*<,8L2'@=[4(\AO\-0"WA11
M%R'ZQ&+F:AJ>C7!3^<+(9]GBZL%SP(6.MIK2[\-VS1]WOFN.BL*!6X7'EP,<
MDD4A>VJ26$ZYA89JU^6.$*^UT#T^J/DHL%)@,^K.-0QD=H7)@AMR.QLN?^3?
M;[/NW"P*^^CA%QR%??3P:Q1V6]3/VSL& 7@"I&7.H]$B.H$<@"B"&UITGZ6Z
M(B4U3':5#A2[2[DYF[L".<ML*?>T=]^HCKQ?)!T7DJL?%!J(+DR)J"-?0<JR
M---\N.Q^=R>H-5]%FK5$DZ5A XX'+574;:_"_#B.E^^3EP !\GFAI'U<P[IQ
MH.3[=8SZ-B&00_ LZ$AG7ML7*>Q>$J1<TB\_482]@RI9>+ZN8^%3#WN/U:WC
M' 1(#+V\!/T-TO<MUB3K2I%,V :"E7/$E6'\07.^$&07Y(_-1"6Q4ON6>S.9
MB8M;<V@4#GM$!V-K1+EA"JCXS5M%ZG!" <RH"-'$GM:$QB.[?C53&:N%4%$P
MJGB9=T*69)S7M$.DVQW#GLD?34,#>G5^@EO<J6808X@L?<,$?!+.A52EWGVT
MQ;<;B%A8O &/OY%(FLH*CVX9R!C4X0)!7^>2C@G@:A'R9#-)<SVN)Z[;4#2W
M]U5Q_!!5&NSN<!FW9=#>3'7\L%YU]+J4+$UMNMRMF3M]_*'0""F.6,(JN@Q
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M]O.F[2;"TM(GG^6[TB6%11;UV@VZ1V+M Y,T&;@7L[BC32VN7=4'@@M>I0)
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MU^@<H5^GHN7P1+Y 0QQT".U\IUJ'4*TX!'TXH(Z-?K#>=!#@J!CYKF #;-I
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M%HX7:@]CBAW".GRA!BB\"2C$P)ET$&IMXU5O7^&)8" (Z2\"]W:IKH)$PDR
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MR'+NLHR8NRECIVU]2!2=(7DC8+%7:%V!L-M&.OB%@9WK88 REF3PJ,.+E'O
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M,#(V,#0P,2YX<V102P$"% ,4    "  LBX=<8=)W_/T*  !_A@  %0
M        @ %6 P  <W5P;BTR,#(V,#0P,5]L86(N>&UL4$L! A0#%     @
M+(N'7)W\M.A8!P  U%<  !4              ( !A@X  '-U<&XM,C R-C T
M,#%?<')E+GAM;%!+ 0(4 Q0    ( "R+AUQ_E+9321<  "ET   2
M      "  1$6  !T;3(V,3$R-S-D,5\X:RYH=&U02P$"% ,4    "  LBX=<
M#QA1+;R<   58@, %0              @ &*+0  =&TR-C$Q,C<S9#%?97@R
<+3$N:'1M4$L%!@     %  4 2 $  'G*      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>tm2611273d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="supn-20260401.xsd" xlink:type="simple"/>
    <context id="AsOf2026-04-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356576</identifier>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-04-01</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-04-01" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-04-01" id="Fact000004">0001356576</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2026-04-01" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2026-04-01" id="Fact000010">2026-04-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2026-04-01" id="Fact000011">Supernus Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-04-01" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2026-04-01" id="Fact000013">001-35518</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-04-01" id="Fact000014">20-2590184</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-04-01" id="Fact000015">9715     Key West Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-04-01" id="Fact000016">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2026-04-01" id="Fact000017">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-04-01" id="Fact000018">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-04-01" id="Fact000019">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-04-01" id="Fact000020">838-2500</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="AsOf2026-04-01" id="Fact000021">Common     Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2026-04-01" id="Fact000022">SUPN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2026-04-01" id="Fact000023">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="AsOf2026-04-01" id="Fact000024">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2026-04-01" id="Fact000025">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2026-04-01" id="Fact000026">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2026-04-01" id="Fact000027">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-04-01" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
